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INTRODUCTION1-7
For many decades treatment of an acute disease or a chronic illness has
been  mostly  accomplished  by  delivery  of  drugs  to  patients  using  various
pharmaceutical  dosage  forms,  including  tablets,  capsules,  pills,  suppositories,
creams, ointments, liquids, aerosols, and injectables, as drug carriers. This type
of  drug  delivery  system is  known  to  provide  a  prompt    release  of  drug  or
immediate release product. Such immediate release products result in relatively
rapid  drug  absorption  and  onset  of  accompanying  pharmacodynamic  effects.
However,  after absorption of  drug from the dosage form is complete,  plasma
drug  concentrations  decline  according  to  the  drug’s  pharmacokinetics  profile.
Eventually, plasma drug concentrations fall below the minimum effective plasma
concentration (MEC), resulting in loss of therapeutic activity. Before this point is
reached another dose is usually given if a sustained therapeutic effect is desired.
An alternative to administering another dose is to use a dosage form that will
provide  sustained  drug  release,  and  therefore,  maintain  plasma  drug
concentrations, beyond what is typically seen using immediate release dosage
forms. In recent years, various modified release and/ or the time for drug release.
After  20th century  investigation  of  new drug  has  been  retained  due  to
investigation  cost  of  new  drug.  Therefore,  pharmaceutical  industries  and
academic  laboratories  have  been  focused  on  establishment  of  novel  drug
delivery  system  /  or  modified  release  dosage  form  rather  investigation  and
development of new drug. 
The basic rationale of a sustained drug delivery system is to optimize the
Biopharmaceutic, Pharmacokinetic and Pharmacodynamic properties of a drug in
such a way that its utility is maximized through reduction in side effects and cure
or control of condition in the shortest possible time by using smallest quantity of
drug, administered by the most suitable route. 
The  novel  system  of  drug  delivery  offer  a  means  of  improving  the
therapeutic effectiveness of incorporated drugs by providing sustained, controlled
delivery and / or targeting the drug to desired site. The goal of any drug delivery
  1
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system is to provide a therapeutic amount of drug to the proper site in the body to
achieve promptly and then maintain the desired drug concentration.
There is a continuously growing interest in the pharmaceutical industry for
sustained release oral drug delivery systems. There is also a high interest for
design a dosage formulation that allows high drug loading, particularly for actives
with high water solubility.
1.1 Modified Release Dosage Form and Drug Delivery3, 8
Drug products designed to reduce the frequency of dosing by modifying
the rate of drug absorption have been available for many years. Early modified
release  products  were  often  intramuscular/subcutaneous  injection  of
suspensions of insoluble drug complexes, e.g. Procaine penicillin, protamine zinc
insulin, insulin zinc suspension or injections of the drug in oil, e.g. Fluphenazine
decanoate.  Advance  in  technology  have  resulted  in  novel  modified  release
dosage  form.  In  contrast  to conventional  (immediate  release)  forms,  modified
release products provide either delayed release or extended release of drug. 
Extended release products are designed to release their medication in a
controlled manner, at a predetermined rate, duration, and location to achieve and
maintain optimum therapeutic blood levels of drug.  
1.1.1 Sustained Release:
The  U.S.  Food  and  Drug  Administration  (FDA)  defines  an  “sustained
release dosage form is one that allows a reduction in dosing frequency from that
necessitated by a conventional dosage form, such as a solution or an immediate
release dosage form”. 
Sustained release tablets and capsules are commonly taken only once or
twice daily, compared with counterpart conventional forms that may have to take
three  or  four  times  daily  to  achieve  the  same  therapeutic  effect.   Typically,
sustained release products provide an immediate release of drug that promptly
produces the desired therapeutic effect, followed by gradual release of additional
amounts of drug to maintain this effect over a predetermined period (Fig 1). The
sustained plasma drug levels provide by sustained release products often times
  2
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eliminates the need for night dosing, which benefits not  only the patients but the
care given as well. 
Time (hr).
Fig. 1: Hypothetical drug blood level – time coverage for a conventional
solid dosage form and a multiple action product. 
Time (hr).
Fig. 2: Hypothetical drug blood level – time coverage for a conventional
solid dosage form and a controlled release product terminology. 
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1.1.2 Pharmacokinetic Simulation Of Sustained Release Products8,3:
The  plasma  drug  concentration  profiles  of  many  sustained  release
products fits an oral one compartment model assuming first order absorption and
elimination. Compared to an immediate release product, the sustained release
product typically shows a smaller absorption rate constant, because of the slower
absorption of the sustained release product.  The time for peak concentration
(tmax) is usually longer (fig-3), and the peak drug concentration (Cmax) is reduced.
If the drug is properly formulated, the area under the plasma drug concentration
curve should be the same, parameters such as Cmax,  tmax  and AUC conveniently
show  how  successfully  the  extended  release  product  performs  in-vivo.  For
example,  a  product  with  tmax  of  3  hours  would  not  be very  satisfactory  if  the
product is intended to last 12 hours. Similarly, an excessively high Cmax is a sign
of dose dumping due to inadequate formulation. The Pharmacokinetic analysis of
single and multiple-dose plasma data has been used by regulatory agencies to
evaluate  many sustained release products.  The analysis  is  practical  because
many products can be fitted to this model even though the drug is not released in
a first order manner. The limitation of this type of analysis is that the absorption
rate constant may not release to the rate of drug dissolution in vivo. 
Time (hr.)
Fig 3. Plasma drug concentration of a SR and a regular release product.
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Various other models have been used to simulate plasma drug levels of
sustained release product (Wellin, 1983).  The plasma drug levels from a zero-
order, sustained release drug product may be simulated with equation (1)
( )kt
D
s
p eKV
DC −−= 1
 ---------- (1)
Where, Ds = maintanance dose or rate of drug release (mg/ml),
            Cp = plasma drug concentration 
             K = overall elimination constant, and 
             VD = volume of distribution
In absence of loading dose, the drug level in the body rises slowly to a
plateau with minimum fluctuations.  
This simulation assumes that 
1) Rapid drug release occurs without delay, 
2)  Perfect zero-order release and absorption of the drug takes place, and
3) The drug is given exactly every 12 hours.
In practice,  the above assumptions are not  precise,  and fluctuations in
drug level do occur. 
When a sustained release drug product with a loading dose (rapid release) and a
zero-order maintenance dose is given, the resulting plasma drug concentrations
are described by:
( ) )1()( ktD
skatkt
D
i
p eKV
D
ee
KKaV
KaDC −−− −+−
−
=
 -------- (2)
Where, Di = immediate – release (loading dose) and 
        Ds = maintenance dose (zero-order).  
This expression is the sum of the oral absorption equation (first part) and
the i.v infusion equation (second part).
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An example of a zero-order release product with loading dose is shown in
fig-4 the contribution due to the loading and maintenance dose is shown by the
dashed lines,  the inclusion of a built-in  loading dose in the extended release
product has only limited use. 
          
                   12              24
                                                   
                                                            TIME ( HOUR)
Fig. 4: Simulated plasma drug level of a SR product with a fast release
component (A) and a maintenance component (B). The solid line
represents total plasma drug level due to the two components.
      
         12          24            36
Fig. 5: Simulated plasma drug level of a SR product administered every 12
hrs. The plasma level shows a smooth rise to steady state level with no
fluctuations. 
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With most sustained release product, the patient is given more than one
dose and there is no need for a built in loading dose with subsequent doses.
Putting a loading dose in the body than necessary, because of the topping, effect
in situations where a loading dose is necessary, the rapid – release product is
used to titrate a loading dose that will bring the plasma drug level to therapeutic
level.
A  Pharmacokinetic  model  that  assumes  first-order  absorption  of  the
loading and maintenance dose has also been proposed.  This model predicts
spiking peaks due to loading dose when the drug is administered continuously
fig-9.
1.1.3 Terminology And Sustained Release Concept3,9-15: 
Over  the  years,  many  terms  (and  abbreviations),  such  as  sustained
release(SR),  sustained action  (SA),  prolonged action  (PA),  controlled  release
(CD),  extended release (ER),  timed release (TR),  and long acting (LA),  have
been used by manufactures to describe product types and features. These are
terms  used  to  identify  drug  delivery  systems  that  are  designed  to  active  a
prolonged  therapeutic  effect  by  continuously  releasing  medication  over  an
extended period of  time  after  administration  of  a  single  dose.  In  the case of
injectable  dosage  form,  this  period  may vary  from days  to  months.  Although
these terms often have been used interchangeably, individual products bearing
these descriptions may differ in design an performance  and must be examined
individually to as certain their respective features.
Sustained release 
In case of sustained release (SR) dosage forms the release of the active
agent, although, is lower than in the conventional formulations, however, it is still
substantially affected by the external environments into which it is going to be
released.  
  7
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Controlled release
Controlled  release  (CR)  systems  provide  drug  release  in  an  amount
sufficient to maintain the therapeutic drug level over extended period of time, with
the  release  profiles  of  predominantly  controlled  by  the  special  technological
construction  and  design  of  the  system  itself.   The  release  of  the  active
constituent is therefore, ideally independent of exterior factors.  
Extended release formulation is a controlled release formulation designed
to produce even and consistent release of active ingredient.  Extended release
(ER) dosage forms are those which due to special  technology of  preparation
provided,  soon  after  a  single  dose  administration,  therapeutic  drug  levels
maintained for 8-12 hours.
Prolonged action
Prolonged or long action products are dosage forms containing chemically
modified therapeutic substances in order to prolong biological half life (Lee and
Robinson, 1987).
These terms are explained in following Fig. 6
Fig. 6 : Relationship between drug concentration and time for Products
Possessing Various Release Profiles
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A -Immediate release    B -Delayed action   C - Repeat action 
D - Prolonged release E - Controlled, sustained release
In general,  the  goal  of  a sustained-release dosage form is to maintain
therapeutic blood or tissue levels of the drug for an extended period.  This is
usually accomplished by attempting to obtain zero-order release from the dosage
form.
Zero-order release constitutes drug release from the dosage form that is
independent of the amount of drug in the delivery system (i.e., a constant release
rate). Sustained release systems generally do not attain this type of release and
usually try to mimic zero-order release by providing drug in a slow first-order
fashion (i.e., concentration-dependent). Systems that are designed as prolonged
release  can  also  be  considered  as  attempts  at  achieving  sustained-release
delivery. Repeat-action tablets are in alternative method of sustained release in
which multiple doses of a drug are contained within a dosage form, and each
dose is released at a periodic interval.  Delayed–release systems, in contrasts,
may not  be  sustaining,  since  often the  function  of  these  dosage  forms is  to
maintain the drug within the dosage form for some time before release. 
1.1.4 CLASSIFICATION10:
Modified Release dosage form may be classified as
A .Delayed release
B. Extended release
B.1: Sustained release
B.2: Controlled release
A. Delayed release: 3  
The drug is  released  at  a  later  time  after  administration.  The delayed
action is achieved by the incorporation of a special coat, such as enteric coating,
or other time barriers such as the formaldehyde treatment of soft and hard gelatin
capsules. The purposes of such preparations are to prevent side effects related
to the drug presence in the stomach, protect the drug from degradation in the
highly acidic pH of the gastric fluid. 
  9
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B. Extended release: B-1): Sustained Release System13-17:
The idealized objective points to the two aspects most important to drug
delivery,  namely,  spatial  placement  relates  to  targeting  a  drug  to  a  specified
organ  or  tissue,  while  temporal  delivery  refers  to  controlling  the  rate  of  drug
delivery to the target tissue. An appropriately designed sustained release drug
delivery can be a major advance towards solving these two problems. The bulk
of  research has been directed at oral  dosage forms that  satisfy the temporal
aspect of drug delivery, but many of the  new approaches under investigation may
allow for spatial placement as well.
The goal of sustained drug delivery are to conserve and maintain effective
drug  concentration,  eliminate  night  time  dosage,  improve  compliance  and
decrease side effects thus, optimizing drug therapy.
Compliance with a drug regimen depends among other things on the route
and  frequency  of  administration,  the  type  of  medication  and  condition  being
treated.  Oral  administration  is  the  most  common technique,  but  patient  often
forget  to  take  their  medication,  and  the  condition,  especially  when  frequent
dosing is required.
Products  that  have  been  formulated  for  the  purpose  of  prolonging
absorption including oral, parenteral, topical and implants dosage form both for
human  and  veterinary  use.  Oral  sustained  release  products  have  gained
importance  because  of  the technological  advances  which  achieve  zero  order
release rate of therapeutic substance. Generally the pharmacokinetics of a drug
is controlled by its chemical nature. However decreasing the absorption rate by
physical  means is  a  useful  method to  sustain  the drug action when  it  is  not
feasible to modify the drug compound at its molecular level.
ADVANTAGES OF SUSTAINED RELEASE DRUG DELIVERY:17-21
The  improvement  in  drug  delivery  is  represented  by  several  potential
advantages as below. 
1. It improves patient compliance.
2. It employs lesser quantity of the drug.
  10
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3. It may improve the pathophysiology of the diseases.
(a) It minimizes or eliminates local side effects.
(b) It minimizes or eliminates systemic side effects.
(c) It  obtains  less  potentiation  or  reduction  in  drug  activity  with
chronic use.
(d) It minimizes drug accumulation with chronic dosing.
4. It improves the efficiency in treatment.
(a) It cures or controls the condition  more promptly.
(b) It improves the control of condition i.e. reduces fluctuation in the
drug level.
(c) It improves bioavailability of some drugs.
(d) Make use of special effects, e.g., sustained release aspirin for
morning relief of arthritis by dosing before bedtime. 
5. Economy:  
(a) In comparison with conventional dosage forms the average cost
of treatment over an extended period may be less. 
(b) Economy also may results from a decrease in nursing time and
hospitalization. Also
 Reduce blood level oscillation characteristic of multiple 
dosing of conventional dosage forms.
 Reduce amount of drug administration 
 Maximizing availability with a minimum dose.
 Control of drug absorption; high peak level peaks that may 
be observed after administration of high availability drug 
can be reduced.  
 Safety margin of high potency drugs can be increased.
 Increased reliability of therapy
6. Improved therapy:
a) Sustained blood level.
  11
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 The dosage form provides uniform drug availability / blood
levels  unlike  peak  and  valley  pattern  obtained  by  intermittent
administration.
b) Attenuation of adverse effects. 
The  incidence  and  intensity  of  undesirable  side  effects
caused by excessively high peak drug concentration resulting from
the administration of conventional dosage forms is reduced.
c) It is seldom that a dose is missed because of non-compliance by
the patient.
          1.2 CONVENTIONAL DRUG THERAPY 4, 22 
In most cases of conventional dosage form the dosing interval  is much
shorter than the half-life of the drug resulting in a number of limitations. 
1. Unless the dosing interval is relatively short, depending on biological
half-life of the drug, large peaks and valleys (Fig.7) in the drug level will
occur.   
2. Success by this approach is dependent on patient compliance with the
dosing  regimen.  Numerous  studies  have  documented  that  lack  of
compliance  is  an  important  reason  for  drug  therapy  inefficiency  or
failure. 
3. During the early periods of dosing there may be insufficient drug to
generate a favorable biological response, which may be a significant
problem in certain disease states. 
4. For drugs with short biological half-lives, frequent dosing is needed to
maintain relatively constant therapeutic levels of drugs. 
There are two ways to overcome such a situation
 Development of new, better and safer drugs with long half-lives and large
therapeutic indices.
  12
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 Effective and safer use of existing drugs through concepts and techniques
of controlled and targeted delivery systems. 
The first approach has many disadvantages, which therefore resulted in
increased interest in the second approach
Fig. (7) A hypothetical plasma concentration – time profile from
conventional multiple dosing and single doses of sustained and controlled
delivery formulations.
1.3 THEORY OF SUSTAINED RELEASE:23,17
Sustained release dosage form may contain:
a) Maintenance dose, and
b) Loading dose
  13
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Fig. (8): Schematic representation of sustained release dosage system.
Time
Fig. (9): A hypothetical plasma concentration time profile from sustained
drug delivery formulation
The maintenance dose or slowly available portion will  release  the drug
slowly and maintain the therapeutic level for an extended period of time. While
the  loading  dose  or  immediately  available  portion  will  held  obtaining  the
therapeutic level quickly after administration.
The rate of release of the drug from the maintenance dosage should be
zero order (independent of the concentration) if the drug at the absorption site is
to remain constant. The release of the drug from the loading dose should follows
first order kinetics.
Sustained action curve is possible only when the drug from the dosage
form is supposed for absorption into the blood, at a constant rate equal to the
  14
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rate constant for the elimination of the drug. From the blood, mathematically this
relationship is given as
K2B=R=KdG------ (3)
Where, K2: Rate constant for elimination of drug from blood. 
  B   :  Quantity of drug to be maintained to the blood
  R   :  Replacement rate
  Kd :   Constant relating the amount that can be absorbed under       
standard volume and concentration conditions
G   : Quantity of drug that the dosage form must supply (maintain) in 
the depot.
When a fraction, f, of the drug is available because of irreversible binding
or degradation, the amount available for absorption must be increased by 1/f.
The value for B is usually known or can be ascertained if the drug and its effect
can be measured.  It is often possible to obtain a value for K2 by plotting a log of
the concentration of the drug remaining in blood versus time.  The negative slope
of the elimination rate constant for design purpose.
When the initial dose (Dn) is estimated from the multiple dose data, the
dose  (Dn)  is  quantity  needed  to  produce  B  (quantity  of  drug  that  must  be
maintained  at  receptor  site).  The  correction  for  irreversible  binding  and  /  or
degradation of the drug in depot (1/f) is not required when Dn is obtained from
multiple dose data.  Ideally,  knowledge of the absorption rate constant K1, the
elimination rate constant (K2) and the distributive rate constant (K12, K 21) should
enable the formulation scientist to construct a curve similar to that given for a
single dose. Number of methods for determining absorption rate constant have
been reported.
The total dose of drug, Dt, in a prolonged action preparation comprises of
the normal dose, Dn, and the sustaining dose Ds i.e.
Dt =Dn +Ds------------ (4)
  15
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For the system where the maintenance dose Ds  provides drug via a zero-
order process the total dose is 
Dt = Dn + Kr0 Td ----------- (5)
Where, Kr0  is the zero-order rate constant for drug release and Td  is the
total time desired for sustained release corresponding to one dosing interval. If
the maintenance dose begins releasing drug at time zero it will add on to that
which is provided by the initial dose, thus pushing the drug level too high.  In this
case  a  correction  factor  is  needed  to  account  for  the  added  drug  from  the
maintenances dose 
Dt = Dn -  Kr0 Tp +  Kr0 Td ------------(6)
Where the correction factor is  the amount of  drug provided,  during the
time period t = 0 to the time of the peak drug level, Tp.  Naturally, if the dosage
form is constructed such that the maintanance dose not begin to release drug
until the peak blood drug level, no correction factor is needed.   
If drug is released via a first-order process, no correction factor is needed.
Vd
K
KeCdDnDt
r
1+=  --------- (7)
Where Ke  is the total elimination constant for the drug, Cd is the desired
blood drug level and K1r  is the first-order drug release rate constant.  The last
term in equation (13) results from the approximation.
Vd
K
KeCdDs
r
1=  --------- (8)
If  the  maintenance  dose  begins  release  of  drug  from  time  zero,  a
correction factor is required similar to the zero-order case. In this case the correct
expression is
d
r
de
pr VK
CKTDsKDnDt 1
1
−=
 ---------- (9)
B-2: Controlled release formulation: 
The controlled release systems is to deliver a constant supply of the active
ingredient, usually at a zero-order rate, by continuously releasing, for a certain
period of time, an amount of the drug equivalent to the eliminated by the body.
  16
Department  of Pharmaceutics
                     Introduction
An ideal controlled drug delivery system is the one, which delivers the drugs at a
predetermined rate, locally or systemically, for a specific period of time. 
Repeat action preparations
A dose of the drug initially is  released immediately after administration,
which is usually equivalent to a single dose of the conventional drug formulation.
After  a  certain  period  of  time,  a  second  single  dose  is  released.  In  some
preparation,  a third  single  dose is  released after  a  certain  time has elapsed,
following  the  second  dose.  The  main  advantage is  that  it  provides  the
convenience  of  supplying  additional  dose(s)  without  the  need  of  re-
administration. It has  disadvantage that the blood levels still  exhibit  the “Peak
and valley” characteristic of conventional intermittent drug therapy. 
1.4 ORAL CONTROLLED RELEASE SYSTEM 10
Oral route has been the most popular and successfully used for controlled
delivery  of  drug because  of  convenience and  ease  of  administration,  greater
flexibility in dosage form design( possible because of versatility of GI anatomy
and physiology) and ease of production and low cost of such a system.
The controlled release systems for oral use are mostly solids and based
on dissolution, diffusion or a combination of both mechanisms in the control of
release rate of drug. 
A. Continuous release systems 
These systems release the drug for a prolonged period of time along the
entire length of GIT with normal transit of the dosage form.
The various systems under this category are:
1. Dissolution controlled release system 
2. Diffusion controlled release system 
3. Dissolution and diffusion controlled release system 
4. Ion exchange resin – drug complexes 
5. Slow dissolving salts and complexes 
6. pH – dependant formulation 
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7. Osmotic pressure controlled systems 
8. Hydrodynamic pressure controlled system 
B. Delayed transit and continuous release system
These systems are designed to prolong their residence in the GIT along
with their release systems included in this category are; 
1. Altered density systems
2. Mucoadhesive systems 
3. Size- based systems
C. Delayed release systems 
The design of such systems involves release of drug only at a specific site
in the GIT. The two types of delayed release systems are;
1. Intestinal release systems 
2. Colonic release systems 
The drugs contained in this system are those that are:
i. Destroyed in the stomach or intestinal site.
ii. Known to cause gastric distress
iii. Absorbed from a specific intestinal site, or
iv. Meant to exert local effect at a specific GI site.
1.4.1 CONTINUOUS RELEASE SYSTEMS:9,25-27
Diffusional System:
Diffusional systems are characterized by the release rate of drug being
dependent on its diffusion through an inert membrane barrier usually; this barrier
is  an  insoluble  polymer.  There  are  basically  two  types  of  diffusion  devices:
reservoir devices and matrix devices. 
 (a) Reservoir devices: 
Reservoir devices, as the name implies, are characterized by a core of
drug, the reservoir,  surrounded by a polymeric membrane.  The nature of the
membrane determines the rate of release of drug from the system. The release
of drug from a reservoir device is governed by fick’s first law of dissolution. 
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The fick’s first law  states that the amount of drug passing across a unit
area  is  proportional  to  the  concentration  difference  across  that  plane.   The
equation is given as  
J = - dX
dCD
  -  - - - - - - - - - - - - -  (10)
Where, J =  flux in units of amount/area-time,
D = diffusion coefficient,
        dX
dC
= change in concentration C relative to distance X in the 
      membrane.
(b) Matrix devices: 
A  matrix  device,  as  the  name  implies  consists  of  drug  dispersed
homogeneously throughout a polymer matrix as represented in following 
figure 
 (Fig. 12).
Fig. (10) - Matrix Diffusion system before drug release (time = 0) and after
partial drug release (time = t)
In this model, drug in the outside layer exposed to the bathing solution is
dissolved first and then diffuse out of the matrix. This process continues with the
  19
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interface between  the bathing solution and the solid  drug moving toward the
interior.
Derivation of the mathematical model to describe this system involves the
following  assumptions:  (a)  a  pseudo-steady  state  is  maintained  during  drug
release, (b) the diameter of the drug particles is less than the average distance of
drug diffusion through the matrix, (c) the bathing solution provides sink conditions
at all times, (d) the diffusion coefficient of drug in the matrix remains constant.
The next equations, which describe the rate of release of drugs dispersed
in an inert matrix system, have been derived by Higuchi. The following equation
can be written based on Fig 4:
                  
2
Cs
dhC
dh
dM
0 −=   ------------------ (11)
Where, dM = Change in the amount of drug released per unit area,
dh  = Change in the thickness of the zone of matrix that has been 
depleted of drug,
C0  = Total amount of drug in a unit volume of the matrix,
Cs  = Saturated concentration of the drug within the matrix.
From diffusion theory,
dt
h
CD
dM sm=
 ----------------------- (12) 
Where, Dm is the diffusion coefficient in the matrix,  Equating Eqs. (1) and (2),
integrating, and solving for h gives
M = [CsDm(2Co-Cs)t]1/2 ------------------(13)
When the amount of drug is in excess of the saturation concentration, that is,
Co>>Cs 
M = (2CsDmCot) 1/2 ---------------------- (14)
Which indicates that among the drug released is a function of the square
root of time. In a similar manner, the drug release from a porous or granular
matrix can be described by
M = 
21
02
/
t)apCC(
T
p
aCsD 



− ---- (15)
Where,   P   = porosity of the matrix,
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   Ca = solubility of the drug in the release medium
   T = tortuosity
   Ds = diffusion coefficient in the release medium.
This system is slightly different from the previous matrix system in that the
drug is able to pass out of the matrix through fluid-filled channels and does not
pass through the polymer directly.
For purposes of data treatment, Eq. (14) or (15) can be reduced to
M = kt1/2------------------------------------ (16)
Where k is a constant, so that plot of amount of drug released versus the
square root of time will be linear, if the release of drug from the matrix is diffusion
controlled.  If this case, then by the Higuchi model, one may control the release
of  drug  from  a  homogeneous  matrix  system  by  varying  the  following
parameters26,  27: (a) initial concentration of drug in the matrix.  (b) Porosity, (c)
tortuosity, (d) polymer system forming the matrix, and (e) solubility of the drug.
E.g. Procan SR.
1.5 MATRIX SYSTEMS:21
A matrix is a uniform mixture of drug and excipients. e.g. polymer that is
homogeneously fixed in solid dosage form.
The drug substance, which has a solubility S gm /cm3  in the dissolution
medium, is dispersed in the matrix which is insoluble in the dissolution medium,
The concentration of drug in the matrix is ‘A’ gm / cm3. The matrix is porous, with
a porosity of  ‘Є’ and diffusion coefficient  of  ‘Dm’.  The drug release from such
system can be described by dQ/dt = 2SDmAt. Liquid will  intrude from the bulk
liquid. The rate and extent of intrusion will follow the following equation:
L
q
L
Qr
dt
dL
−=
−
= η8
2
 ------------------------ (17)
Where, L is the length of the intrusion at time t, r is the average radius of
the pores, ŋ is the viscosity of the liquid and Q is a constant. 
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Fig. (11): Dissolution of drug from a solid matrix
1.5.1  HYDROPHILLIC MATRIX SYSTEM:28,29
A  hydrophilic  matrix  controlled  release  system  is  a  dynamic  system
composed of polymer wetting, polymer hydration and polymer dissolution. At the
same time other soluble excipients or drug will also wet, dissolve and diffuse out
of the matrix while insoluble materials will be hold in place until the surrounding
polymer/ excipients / drug complex erodes or dissolves away.
The main principle is that a water-soluble binder, present throughout the
tablet, partially hydrates on the outer tablet “sink” to form a gel layer. Throughout
the life of ingested tablet the rate of drug diffusion (if soluble) out of the wet gel
and  the  rate  of  tablet  erosion  control  the  overall  dissolution  rate  and  drug
availability.
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Fig. (12) :  Matrix System
The most common controlled delivery system has been the matrix type
such as tablets and granules, where the drug is uniformly dissolved or dispersed
through  out  the  polymer,  because  of  its  effectiveness,  low  cost,  ease  of
manufacturing and prolonged delivery time period.
Hydrophilic  polymers  are  becoming  more  popular  in  formulating  oral
controlled release tablets, it is well documented that the dissolution curve of drug
release from a hydrophilic  matrix shows a typical  time dependent profile.  The
release of a dissolved drug inherently follows near first order diffusion either an
initially high release rate, due to the dissolution of the drug present at the surface
of the matrix followed by a rapidly declining drug release rate. The enhanced
release rate observed at the beginning for the short time of release process is
known as “burst  effect”  and is  many a  time undesirable  since it  may,  have
negative  therapeutic  consequences.  After  this  burst  effect,  hydration  and
  23
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consequent  swelling  and/or  erosion  of  related  polymer  occur.  These
phenomenon’s control the release process but with time, the diffusion path length
increases  and  saturation  effect  is  attained,  resulting  in  a  progressively  slow
release rate during the end of dissolution span.
Fig.(13): Schematic showing the burst effect in a zero-order 
Drug delivery system.
In many controlled release formulations immediately upon placement in
release medium, an initial large bolus of drug is released before the release rate
reaches a stable profile. This phenomenon is referred to as ‘burst release’.
 
SWELLABLE MATRICES AS SYSTEMS FOR ORAL DELIVERY31-42
Monolithic  devices or matrices represent  a substantial  part  of  the drug
delivery  systems.  Matrices  containing  swellable  polymers  are  referred  to  as
hydro gel matrices, polymeric matrices involving moving boundaries, hydrocolloid
matrices,  swellable  controlled  release  systems  or  hydrophilic  matrix  tablets.
Swellable matrices for oral administration are commonly manufactured as tablets
by the compression of hydrophilic micro particulate powders. Therefore, the most
appropriate classification for these systems is swellable matrix tablets. They are
constituted of a blend of drug and one or more hydrophilic polymer. In general
drug release from swellable matrix tablets is based on glassy-rubbery transition
of polymer as a result of water penetration into the matrix. Whereas interactions
  24
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between water,  polymer and drug are  the primary factors for  release control,
various formulations variables, such as polymer grade, drug/polymer ratio, drug
solubility, and drug and polymer particle size, can influence drug release rate to
greater or lesser degree. However the central element of the mechanism of drug
release is the gel layer (rubbery polymer),  which is formed around the matrix.
The gel  layer  is  capable  of  preventing matrix  disintegration and  further  rapid
water  penetration.  Water  penetration,  polymer  swelling,  drug  dissolution  and
diffusion and matrix erosion are the phenomena determining gel layer thickness.
Finally, drug release is controlled by drug diffusion through the gel layer and/or
by erosion of  the gel  layer.  In order to follow gel  layer  dynamics during drug
release in swellable matrices, the boundaries of such a layer have to be defined.
It  is  well  known that  gel  layer is  physically delimited by two sharp fronts that
separate-different  matrix  states,  i.e.  the  boundaries  separating swollen  matrix
from solvent  and glassy from rubbery polymer.  However the possibility  of  the
presence of a third front inside the gel layer has been described. This additional
front was termed undissolved drug front or diffusion front and turned out to be a
function of drug solubility and loading. Its presence can create conditions such
that  the  release will  be  more  controlled  by drug  dissolution  than by polymer
swelling. Thus in swellable matrix tablet three fronts could be expected: 
1. The swelling front, the boundary between the still glassy polymer and
its rubbery state,
2. The diffusion front, the boundary in the gel layer between the solid, as
yet undissolved drug and the dissolved drug and 
3. The erosion front, the boundary between the matrix and the dissolution
medium.
The  measurement  of  front  positions  gives  the  possibility  to  determine
three important parameters related to the behavior of the matrix, i.e. the rate of
water  uptake,  the  rate  of  drug  dissolution  and  the  rate  of  matrix  erosion,
associated with the movements of the swelling front, diffusion front and erosion
front  respectively.  These  parameters  are  strictly  linked  to  the  drug  release
kinetics from  matrix.
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Many attempts have been made in order to control the movement of the
fronts and therefore the drug release kinetics. The more successful consists in
the reduction of the matrix-swelling rate by partially coating the matrix surface
with impermeable or slowly permeable polymeric layer. In this way drug release
can be modulated and the release kinetics can be shifted toward the linearity.
1.6 MECHANISM OF DRUG RELEASE FROM MATRIX SYSTEM:31,51-58
    When a hydrophilic matrix system containing a swellable glassy polymer
comes  in  contact  with  an  aqueous  medium,  the  fall  in  glass  transition
temperature leads to an abrupt change from a glassy to a rubbery state, causing
swelling of the polymer on the surface and formation of a hydrated gel.  Drug
release is controlled by this gel diffusional barrier and/or by surface erosion of the
gel. Surface leaching of the drug can lead to an initial burst, especially with highly
soluble drugs.
Hydration of individual polymer chains leads to expansion in their end to
end distance and radius of gyration to a new solvated state due to lowering of the
polymer transition temperature, a sharp distinction between glassy and rubbery
region is observed and the matrix increases in volume because of swelling.
 As water infiltrates deep in to the core, the thickness of the gel  layer
increases with simultaneous dissolution and erosion occurring at the outer layer
due to complete hydration.
When the system is  hydrated to  the core,  the  drug concentration falls
below its solubility value and the release rate of the drug begins to decline. A
concurrent increase in the thickness of the barrier layer with time increases the
diffusion  path  length,  further  reducing  the  release  rate.  Drug  release  kinetic
associated with this gel layer dynamics, range initially from Fickian to anomalous
(Non-Fickian)  and  subsequently  from  quasi-constant  (near  zero  order)  to
constant.  Matrices of  highly molecular weight  polymers rarely shows all  three
regimens (Fickian, Non-Fickian and quasi-constant) of drug release because of a
low chain disentanglement rate and insufficient external polymeric mass transfer.
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 Soluble drugs are primarily released by diffusion through aqueous filled
porous network formed in the inert matrix former due to dissolution and erosion
of  the polymer  from the surface.  Far  poorly  soluble  drugs  dispersed in  inert
polymer systems erosion is the primarily release mechanisms.
There are two major processes that control the drug release from swelling
controlled matrix systems, these include:
1. Ingress of aqueous medium into the matrix followed by a hydration,
gelation or swelling and
2. Matrix erosion.
Simultaneous occurrence of these processes leads to the formation of two
fronts within the hydrating matrix, this are- a swelling front, at the junction of the
unhydrated glassy matrix and the hydrated matrix and an eroding front where
the  polymer  is  completely  hydrated.  Thickness  of  the  diffusion  layer,  i.e.  the
distance  between the  two  fronts,  depends  on  the  relative  rates  at  which  the
swelling and erosion occurs.
If  the  polymer gels  slowly,  solvent  can penetrate  deep  into  the glassy
matrix, thus dissolving the drug; therefore, gel layer thickness and its stability are
crucial  in controlling drug release. Numbers of techniques have been used to
study the swelling of matrix tablets and to characterize the gel layer and front
movement such as, optical imaging,
 
1H- NMR, pulsed –filled gradient spin echo
NMR,  confocal  laser  scanning  microscopy,  cryogenic  scanning  electron
microscopy and texture analysis. The gel layer thickness is determined by the
relative position of the swelling and erosion front.
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ADVANTAGES OF HYDROPHILIC MATRIX SYSTEM:-
A hydrophilic matrix system essentially consists of a drug dispersed in a
water swelling viscous polymer. These systems offer a number of advantages
over other sustained release technologies namely.
1. Simplicity of formulation.
2. High drug loading as high as 80 % is possible in many cases.
3. The  system  is  usually  inexpensive  as  the  rate-controlling  agent  is
usually a GRAS (generally accepted as safe) food polysaccharides.
4. Number  of  matrix  former  is  available  allowing  development  of
formulations that meet special needs and avoid patent infringement.
5. The  systems  are  eroded  as  they  pass  the  GIT  thus  there  are  no
accumulation of “Ghosts” or empty shells.
6. As system depends on both diffusion and erosion for drug release,
release is not totally dependent on GI motility.
7. No  specialized  equipment  is  required  which  substantially  reduces
manufacturing costs.
8. Offer  easy  scalability  and  process  validation  due  to  simple
manufacturing processes.
The above listed advantages overshadow the undesirable property
of reducing release rates with time.
FACTORS INFLUENCING DRUG RELEASE FROM MATRIX SYSTEMS57:-
A number of formulation variables and properties of the rate controlling
polymer and the drug itself can be altered to attain a desired release rate from a
matrix  system.  The mechanism by which  drug release is  controlled  in  matrix
tablets are  dependent  on many variables,  these variables are summarized in
figure
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Fig. (15) : Summary of factors influencing release rate from 
Matrix systems.
1.7  Criteria  to  be  met  by  drug  proposed  to  be  formulated  in
sustained release dosage forms. 59-63 
a) Desirable half-life:
 The half life of a drug is an index of its residence time in the body. If the
drug has a short half life (less than 2 hours), the dosage form may contain a
prohibitively large quantity of the drug. On the other hand, drug with elimination
half  life  of  eight  hours  or  more  are  sufficiently  sustained  in  the  body,  when
administered in conventional dosage from, and controlled release drug delivery
system is generally not necessary in such cases. Ideally, the drug should have
half-life of three to four hours.
b) High therapeutic index                                                                                    
Drugs with low therapeutic index are unsuitable for incorporation in 
controlled release formulations. If the system fails in the body, dose dumping 
may occur, leading to fatalities eg. Digitoxin.
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c) Small dose:
If the dose of a drug in the conventional dosage form is high, its suitability
as a candidate for controlled release is seriously undetermined. This is chiefly
because the size of a unit dose controlled release formulation would become too
big, to administer without difficulty.
d) Desirable absorption and solubility characteristics:
Absorption of poorly water soluble drug is often dissolution rate limited.
Incorporating such compounds into controlled release formulations is therefore
unrealistic and may reduce overall absorption efficiency. 
e) Desirable absorption window:
Certain drugs when administered orally are absorbed only from a specific
part of gastrointestinal tract. This part is referred to as the ‘absorption window’.
Drugs  exhibiting  an  absorption  window  like  fluorouracil,  thiazide  diuretics,  if
formulated as controlled release dosage form are unsuitable.
f) First pass clearance:
As  discussed  earlier  in  disadvantages  of  controlled  delivery  system,
delivery of the drug to the body in desired concentrations is seriously hampered
in  case  of  drugs  undergoing  extensive  hepatic  first  pass  metabolism,  when
administered in controlled release forms.
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AIM AND OBJECTIVE
Aim of work
In pharmaceutical practice several approaches exist for administration of
drugs to the patient.  If the drug is given in conventional dosage form it has to be
administered several time to produce desired therapeutic effect. Because of this
frequent  dosing  fluctuation  in  plasma  drug  level  occur.  The  pronounced
fluctuation resulting from the conventional drug administration are likely to yield
period of therapeutic effects, when the concentration falls below the minimum
therapeutic  level.   Drug  concentration  can  be  controlled  within  the  narrow
therapeutic range by the use of sustained release systems, which will minimize
the severity of side effects
Aceclofenac is an Non Steroidal Anti Inflammatory Drug , with half life of
4  –  4.3  hours  and requires Single  daily  doses  to  maintain  adequate  plasma
concentrations.  So it is selected to prepare a sustained release tablets.  The
objective of this present study to develop a competitive sustained release tablets
Aceclofenac which release the drug in a sustained manner over a period of 24
hours, by using different polymers and study on there effect on release pattern.
                  Department of Pharmaceutics    31
Department  of Pharmaceutics
                     Plan of work
                                             3. PLAN OF WORK
The following experimental protocol was therefore designed to all
systematic approach to the study.
1) Drug selection
2)  Literature Survey:-
3) Preformulation study: Compatibility evaluation was carried out   between       
drug and polymers in physical observation and by using FT- IR spectral study.
4) Preparation of standard curve for Aceclofenac in phosphate buffer pH 6.8 .
5) Formulation development of sustained release matrix tablets of using    
different release retardant.
6) The following evaluation parameters were studied based on laboratory 
      experiments.
i) Evaluation of granules
  Angle of repose
 Apparent bulk density
 Tapped bulk density
 Percent compressibility
 Loss on drying 
 Hausner Ratio
ii) Evaluation of tablets
 Tablet dimensions
 Hardness
 Friability
 Weight variation
 Content uniformity of active ingredient 
  In-vitro dissolution study
7)    Stability study of optimized batch
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                                         4.  LITERATURE REVIEW:
 S. Indiran Pather  64   et.al   (1998)  have formulated sustained release
theophylline tablet by direct compression using ethyl cellulose as polymers they
found that  In addition matrices of  this polymer display slow surface erosion
which can be enhanced by the incorporation of a swelling agent.  This property
was utilized in an attempt to decrease the attenuation of the release rate that is
observed with  matrix tablets that follow the Higuchi  pattern of drug release.
The release rate decreases because of the external layers of the tablet become
depleted and water must penetrate the deeper layers of the tablet to reach the
remaining  drug.   The  Theophyline  to  ethyl  cellulose  ratio  and  the  tablet
hardness were found to influence the rate of drug release.
 Yihong qiu  . 65   et.al  (1998)  have used different viscosity grades of
HPMC.  Along with other excipient including Avicel and lactose for zero order
sustained delivery of. Pseudoephedrine HCl they shown that zero – order or
near zero – order drug release can be obtained using the new layered matrix
designs.  In general linear release profiles were observed with the HML and
HMH  systems.   However,  formulation  and  matrix  variables  in  the  barrier
layers need to be adjusted for achieving zero – order drug release from the
LML system
 Philip J. Cox  66   et.al(1999) have prepared mini matrix of Ibuprofen
by wet  granulation technique in which hydrophillic  matrix was  formed with
HPMC. xanthan and Karaya gum along with Avicel PH 101 and found that
S(+)  ibuprofen  mini  –  matrices  can  be  produced  by  the  wet  granulation
method using xanthan gum, karaya gum or HPMC as the retarding agents.
The crushing strengths used were in the range 23.3 – 28.0 N. Xanthan gum
produced a greater sustaining effect on the release of S (+)Ibuprofen than
Karaya gum.
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 T.Sing  Hua  67    et.al  (2000)  have  prepared  sodium  valproate
sustained release tablets. The release curve of sustained release tablets were
consistent with Depakine Chrono. The pharma cokinetics and bio availability of
sustained release tablets was evaluated using the conventional  tablets. The
plasma concentration were determined by HPLC after a randomized cross over
oral  administration  of  a  single  dose  of  sustained  release  tablets  and
conventional tablets in healthy volunteers.
 Silvina A. Bravo  68   et.al (2002) have achieved zero order release of
diclofenac sodium by using HPMC matrix  in  different  content  level  of  MCC.
Starch and lactose. they studied that Drug release from swollen matrices was
principally regulated by starch (17%)j or lactose (17%), even on the presence of
MCC at  different  levels  (5% or  7.5%).   However,  when  starch (8.5%) and
lactose (8.5%) were mixed at lower concentration in a  ratio 1:1, MCC (5%
or7.5%) appeared to control the drug release from  the matrices.
 K.  Raghuram  Reddy  69  et.al  (2003) have  developed  sustained
release  matrix  tablet  of  nicorandil  by  wet  granulation  technique  they  used
HPMC SCMC and sodium alginate as matrix material for granulation they use
ethanolic  solution of  EC and PVP.  they found that  the hydrophilic  matrix  of
HPMC alone could not control the nicorandil release effectively for 24hours.  It
was evident from the results that a matrix tablet prepared with HPMC and a
granulating agent of a hydrophobic polymer (EC, 4% wt / vol) is a better system
drug like nicorandil.
 Owen  .I  Corrigan  70   et.al  (2004) have  studied  the  swelling  and
erosion   properties  of  HPMC.  In  different  agitation  rate  and  dissolution
medium composition.  In their current  work,  swelling and erosion of  HPMC
polymers of differing molecular weights were examined by measuring the wet
and subsequent dry weights of matrices.  The polymers used were K 100 m,
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K 15M, K4M, K100 LV and a low viscosity polymer, E50LV, which is slightly
more hydrophobic due to increased methoxy substitution.  These polymers
show a wide range of viscosity’s, reflecting molecular weight  which causes
differences in their swelling and erosion behaviors.
 Fenq XM  71   et.al (2006) was prepared and evaluate a new delayed
onset sustained release system of  propranolol  Hydrochloride comprising a
sustained release core tablet with HPMC as polymer matrix and an Eudragit
polymer coating capable of delaying the drug release
 Hosseinali  Tobandeh   72    et.al  (2006)  have  prepared  sustained
release  matrix  tablets  of  aspirin  with  ethyl  cellulose,  Eudragit  RS100 and
Eudragit S100 and studying the release profiles and their sensitivity to tablet
Hardness 
 Srinivasa  Mutalik  73   et.al  (2006) investigation  was  to  prepare
glipizide matrix transdermal systems using Eudragit RL – 100/ Eudragit RS
-100.  The  systems  were  evaluated  for  various  in  vitro  and  in  vivo  ,
biochemical parameters. The in vivo results released severe hypoglycemia in
the initial hours and they were also effective on chronic application. 
 Varshosaz Jaleh  74   et.al (2006) Used hydrophilic natural gums such
as HPMC.  Guar gum and xanthan gum for sustaining release of tramadol
hydrochloride in matrix form and find that Guar gum alone cannot efficiently
control drug release, and Xanthan gum has higher drug retarding ability than
Guar gum .  The Combination of each n gum with HPMC leads to a greater
retarding effect as compared with a mixture of  2 natural gums.
 Yeole PG  75   et.al (2006) developed sustained release matrix tablet
of diclofenac sodium by using xanthan gum as a matrix former and micro
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crystalline cellulose as diluent. The inverse relationship was found between
amount of gum and release rate of diclofenac sodium. Increasing the amount
of gum in the formulation form 0.12% w/w to 0.28% w/w resulted in slower
rate and decreased amount of drug release from the tablet.
 Achutha Nayak Usha  76    et.al (2007 )  have prepared Aceclofenac
agglomerates  by  spherical  crystallization  technique  using  a  three  solvent
system  comprising  acetone,  dichloromethane  water,  Hpmc  –  50  cps.  In
different  concentration  was  used  as  a  hydrophilic  polymer.  The  effect  of
speed of rotation and  amount of bridging liquid on spherical agglomeration
were studied. The agglomerates were subjected to various physicochemical
evaluation such as practical yield, drug content, LOD, IR , Spectroscopy, DSC
and  Dissolution studies.  The agglomerates showed improved micromeritic
properties as well  as dissolution behaviour.  In comparison to conventional
drug crystals.
 Mandal U  77   et.al (2007)  have design oral sustained release matrix
tablets of metformin hydrochloride and to optimize the drug release profile
using  response  surface  methodology.  Tablets  were  prepared  by  non  –
aqueous wet granulation method using HPMC K – 15M as matrix forming
polymer.  The  evaluation  parameter  helped  in  finding  the  optimum
formulation with sustained release Drug.
 Srinivasa  Mutalik  78   et.al  (2007) studied  the  significant  effect  of
chitosan  on  improving  the  dissolution  rate  and  bioavailability  of
aceclofenac  .  Chitosan  was  precipitated  on  aceclofenac  crystals  using
sodium citrate  as the salting out  method with  different  concentrations of
chitosan were characterized in terms of solubility, X –ray diffraction etc. was
assessed  by  preclinical  pharmacodynamic  (  analgesic  and  anti  –
inflammatory activity). The in vivo studies revealed that the optimized crystal
37
Department  of Pharmaceutics
             Literature Review
formulation  provides  rats  besides  exhibiting  improved  pharmacokinetic
parameters in rats. 
 S  Mutalik  79  et.al  (2007)  studied  was  to  develop  “once  daily”
sustained release tablets of aceclofenac hydroxyl profile  methyl cellulose –
K4  M  (HPMC).  The  solubility,  in  vitro  drug  release  ,  analgesic,
pharmacokinetic  and toxicity  studies and clinical  pharmacokinetic  studies
were conducted.
 
 Venkadari  Gupta  80  et.al  (2007) prepared  Celecoxib  spherical
agglomerates with  polyvinylpyrrolidone (PVP)  using acetone  ,  water  and
liquid  respectively.  The  agglomerates  were  characterized  by  differential
scanning  calroimetry  (DSC)  etc.  The  results  indicated  the  absence  of
studies showed a decrease in crystallinity in agglomerates. An increase in
PVP concentration the studies showed that the crystal possess surface. 
 Meyyanathan S.N  81   et.al (2008) have prepared sustained release
matrix tablets of Dextromethorphan hydrobromide by wet granulation using (
HPMC k – 100) as the hydrophillic rate controlling polymer. The physical
parameter and invitro  dissolution were studied .The extent of Absorption of
drug from the sustained release tablets was significantly higher than that for
marketed  Dextromethorphan  hydrobromide  tablets  because  of  lower
elimination rate and longer half life.
 Li CJ  82   et.al (2008) have prepared verapamil Hydrochloride in cup
tablet with tri layered tablet and core tablet  separately which can provide
biphasic release with double pulsatile and multiphasic release, core tablets
were prepared by direct compression method and core in cup tablets by dry
compression coated technology. The release rate increased with HPMC K –
100. This is determined by erosion rate of inhibitor layers.
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 Tiwari S. B.  83   et  al, studied the effect of concentration of hydrophilic
(hydroxypropyl  methyl  cellulose  [HPMC]  and  hydrophobic  polymers
(hydrogenated castor oil [HCO], ethyl cellulose). Hydrophobic matrix tablets
resulted in sustained in vitro drug release (>20 hours) as compared with
hydrophilic  matrix tablets (<14 hours).  The presence of  ethyl  cellulose in
either of the matrix systems prolonged the release rate of the drug. The
effect of ethyl cellulose coating (Surelease) and the presence of lactose and
HPMC in the coating composition on the drug release was also investigated.
Hydrophobic matrix tablets prepared using HCO were found to be the best
suited  for  modulating  the  delivery  of  the  highly  waster-soluble  drug,
tramadol hydrochloride
 Mandal U  84   et.al, studied a fixed dose combination of bilayer matrix
tablets of metforming sustained release and glipised as immediate release
with HPMC k – 15 M and HPMC K- 100M. In this three different grades of
HPMC (HPMC  K - 4M, HPMC  K – 15M and HPMC  K – 100M ) were used.
By using polymer tablet shows release profile. 
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CHAPTER 5
EXPERIMENTAL INVESTIGATION
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5.1 Materials Used in study 
Table 1
Material Used
Sr.No MATERIALS USED
1. Aceclofenac
2. Microcrystalline cellulose (Avicel pH 101)
3. PVP k 30
4. HPMC K 4M
5. HPMC  K 15M
6. Acrypol  934 P
7. Aerosil
8. Isopropyl  Alchol
ALL THE CHEMICALS USED IN UNIT WERE OF ANALYTICAL 
GRADE AS PER INDUSTRY SPECIFICATIONS.
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                         5.2. Instruments Used in study:
Table No. 2
Instruments Used
Sr. No INSTRUMENTS MANUFACTURER
1 Electronic  Balance  &  Top  loading
Balance,
Shimadzu  Corporation,  AW
220 and BX 6205
2 Tray Dryer Erweka Pvt. Ltd.
3 Coating machine Erweka Pvt. Ltd.
4 Dissolution  Apparatus  (USP)  Auto
Sampler
Electrolab Pvt. Ltd.
5 Shaking Water Bath Equitron
6 Tablet Hardness tester Monsanto
7 Friability test apparatus Electrolab  Pvt.  Ltd.  EF  2
USP
8 Ultra Violet Visible spectro photometer Shimadzu  Corporation  UV-
1700
9 FT-IR Spectrophotometer Shimadzu  Corporation,
8400S
10 Tap density Appratus Erweka Pvt. Ltd.
11 Granulate Flow Tester Erweka Pvt. Ltd.
12 Vernier Caliper Digimatic
13 pH Meter, Systronics (335)
14 LOD apparatus Sartorius
15 Tablet punching machine CADMACH 16 station
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5.3 DRUG PROFILE 85-88
ACECLOFENAC
Aceclofenac  is  one  of  the  emerging  NON  STEROIDAL  ANTI
INFLAMMATORY  DRUG   molecules  for  arthritis  treatment.  it  is  a  newer
derivative  of  diclofenac  and  has  less  gastrointestinal  complications.  the
successful treatment of arthritis depends on the maintenance of effective drug
concentration level in the body for which a constant and  uniform supply of
drug is desired. Sustained release dosage forms deliver the drug at a slow
release rate over an extended period of time and achieve this objective. the
short biological half-life 9about 4 h) and dosing frequency more than one per
day make aceclofenac an ideal candidate for sustained release. 
To  reduce  the  frequency  of  administration  and  to  improve  patient
compliance,  a  once-daily  sustained  release  formulation  of  aceclofenac  is
desirable. For sustained release systems, the oral route of drug administration
has,  by  far,  received  the  most  attention  as  it  is  natural  uncomplicated,
convenient  and  safer  route.  Matrix  tablets  composed of  drug  and  release
retarding  material  offer  the  simplest  approach  in  designing  a  sustained
release system. Matrix tablets are prepared by wet granulation.
The objective of the present study was to develop “one daily” sustained
release tablets of  aceclofenac by wet granulation.  The solubility  studies of
aceclofenac were conducted to select suitable dissolution media. The drug
excipient mixtures were subjected to preformulation studies. The tablets were
subjected to physicohemical, in vitro drug release and stability studies.
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Structural  Formula:  
Official    In Indian Pharmacopoeia
Molecular formula    C16H13C12N04
Molecular weight    354.19
Chemical name              (2,6-dichlorophenyl)aminophenylacetoxyacetic
acid
Solubility Drug is freely soluble in acetone and insoluble in
water
Appearance    White or almost white powder
Shape    Crystalline Powder
Identification    When examined in the range of 220 nm to 370  
nm.   
The 0.002% w/v solution in Methanol shows  
Maximum absorption at 275 nm
   It contains not less than 99.0% not more than 
101.0% of its compounds  calculated on the dried
basis (IP 2007)
Biopharmaceutical             Class  Second  (High  Permeability  and  Low
Solubility)
Classification    
Category First –line drugs in the symptomatic treatment of
rheumatoid arthritis, osteoarthritis and ankylosing
spondylitis.                
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Mechanism of pain & Inflammation:
Prostaglandins are implicated in  the inflammatory response and are
sensitizing  nociceptors  to  the  actions  of  other  Mediators,  occurring  during
acute and chronic inflammatory illness, prostaglandins are produced at the
site of inflammation where it is believed that they mediate many of symptoms
of inflammation such as oedema and pain. 
Arachidonic acid is released from cell membranes by phospholipases,
cyclooxygenases  catalyze  the addition  of  molecular  oxygen  to  arachidonic
acid to form in initially the endoperoxide intermediate prostaglandin G2. The
same  enzymes  also  process  peroxidase  activity,  which  catalyzes  the
reduction of these prostaglandins to form PGH2. PGH 2 may then react with a
number  of  enzymes  sometimes  called  isomerases  to  become one  of  the
prostaglandins or thromboxanes. 
Clinical Pharmacology :
Pharmacodynamics –
Aceclofenac  is  a  novel  NSAIDS  known  to  exhibit  multifactor
mechanism of action.Aceclofenac was developed in order to provide a highly
effective pain relieving therapy with a reduced side effect profile
 1.Aceclofenac  directly  blocks  PGE2  secretion  at  the  site  of
inflammation  by  inhibiting  IL-1  BETA  &  TNF  in  the  inflammatory
cells(Intracellular  Action).Aceclofenac  has  been  demonstrated  to  inhibit
cyclooxygenase  (COX)  activity  and  to  suppress  the  PGE2  production  by
inflammatory  cells,which  are  likely  to  be  a  primary  source  of
PGE2.Aceclofenac  and  4-hydroxyaceclofenac  penetrates  the  inflammatory
cells like active metabolites diclofenac and 4-hydroxydiclofenac which inhibit
IL-1  and  TNF  released  by  the  inflammatory  cells  and  therefore  suppress
production of PGE2 at the site of inflammation.
2. Aceclofenac stimulates the synthesis of the extracellular matrix of
the Human Articular Cartilages.
45
Department  of Pharmaceutics
                                                                                         Experimental Investigation
Aceclofenac  blocks  degeneration  and  stimulates  synthesis  of  extracellular
matrix of cartilages by inhibiting the action of different cytokines.Aceclofenac
and the metabolites inhibit IL-6 production by human chondrocytes.This leads
to inhibition of increase of inflammatory cells in synovial tissue,inhibition of IL-
1  amplipification,inhibition  of  increased  MMP  synthesis  and  thus  ensuring
proteoglycan production.Aceclofenac also inhibit IL-1 and TNF production by
human  chondrocytes,inflammatory  cells  and  synovial  cells  and  therefore
blocks  suppression  of  GAG and collagen synthesis  and stimulates  growth
factor  mediated  synthesis  of  GAG  and  collagen.4`-hydroxyaceclofenac,a
metabolite  of  aceclofenac inhibits  pro  MMP1 and  pro  MMP3 produced by
synovial cells (Rheumatoid Synovial Cells ) in serum and in synovial fluid and
thus inhibits progressive joint destruction by MMPs.
3.Aceclofenac  inhibits  Neutrophil  Adhesion  &  Accumulation  at  the
inflammatory site in  the early phase and thus blocks the pro-inflammatory
actions of Neutrophils.
Pharmacokinetic Profile:
Absorption:
Oral Absorption : Rapidly absorbed orally
Oral Bioavailability : Almost 100%
Distribution:
Plasma protein binding   99.7%
Volume of distribution : 20-30 L
Effective Concentration : 60% 
Metabolism : Aceclofenac is probably metabolized via CYP2C9 to the main
metabolite 4-hydroxyaceclofenac.
Elimination:
Plasma half life : 4 – 4.3 hours
Excretion : Urinary 95 %
46
Department  of Pharmaceutics
                                                                                         Experimental Investigation
Dosage and Administration
The  dose  of  Aceclofenac  SR  should  be  titrated  according  to  the
severity of the pain and the clinical response of the individual patient.  The
recommended dose of Aceclofenac SR in adults and adolescents over the
age of 12 years in 200 mg once a day. The tablets are to be taken whole, not
divided or chewed, with sufficient liquid, irrespective of food intake. 
Indications : Relief of moderate to severe pain.
Contraindications
Aceclofenac  is contraindicated in:
 Individuals with known hypersensitivity to Aceclofenac or any of its 
excipients
 In patients in whom substances with a similar action (e.g. Aspirin or
other  NSAIDS)  precipitate  attack  of  asthma,bronchospasm,acute
rhinitis or urticaria 
 Severe  heart  failure  or  severely  impaired  hepatic  or  renal  organ
function
 Aceclofenac  must  not  be  used  during  the  last  three  months  of
pregnancy..
Adverse Effects:
 Generally mild:epigastric pain,nausea,headache,dizziness,rashes.
 Gastric ulceration and bleeding are less common.
 Reversible elevation of serum amino-transferases can occur.
 Kidney damage is very rare.
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USES
 IN OSTEOARTHRITIS
 IN RHEUMATOID ARTHRITIS
 IN ANKYLOSING SPONDYLITIS
 IN DENTAL PAIN
 IN POSTOPERATIVE PAIN
 IN DYSMENORRHOEA
 IN ACUTE LUMBAGO
 IN MUSCULOSKELETAL TRAUMA
 GONALGIA (KNEE PAIN)
Aceclofenac SR tablets are available at strength 100mg or 200mg dose in the 
market
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                              5.4 POLYMER PROFILE 89-92,61
1) HYDROXYPROPYL METHYLCELLULOSE:
It is also called as methyl hydroxypropylcellulose, propylene 
glycol ether of methylcellulose, methylcellulose propylene glycol ether. 
Chemically it is cellulose, 2-Hydroxypropyl methyl ether, cellulose 
Hydroxypropylmethylether.
Empirical Formula: C8H15O6 – (C10H18O6) n – C8H15O5
Description: It is an odorless tasteless, white or creamy white fibrous or 
granular powder
Molecular Weight : 86,000
Bulk Denisity 0.25-0.75 g/cm3
Solubility
Soluble in cold water forming a viscous colloidal solution, insoluble in alcohol, 
ether and chloroform, but soluble in mixtures of methyl alcohol and methylene
chloride. Certain grades are soluble in aqueous acetone, mixtures of 
methylene chloride and isopropyl alcohol and other organic solvents
Viscosity: 2% solution
HPMC K100M –80000-120000 cps
HPMC K15M-11250-21000 cps
HPMC K4M-3000-5000 cps
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Stability and Storage Conditions: 
Very  stable  in  dry  conditions.  Solutions  are  stable  at  PH  3.0-11.0.
Aqueous solutions are liable to be affected by microorganisms. When used as
a viscosity increasing agent in ophthalmic solutions, an anti-microbial agent,
such  as  benzalkonium  chloride,  should  be  incorporated.  Store  in  a  tight
container, in a cool place.
Incompatibility:
Extreme pH conditions, oxidizing materials. 
Uses:
It is used as film former (2-10%), binder (2-5%). High viscosity grades
are used to retard  the release of  water-  soluble  drugs.  It  is  also used as
emulsifier, suspending agent and stabilizer in gels and ointments Adhesive in
plastic bandages.  
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2) MICROCRYSTALLINE CELLULOSE
Synonyms  :  Avicel, Crystalline cellulose Emcocel
Description :  It is purified, partially depolymerised cellulose, which occurs as
white, odorless, tasteless, dry powder composed of porous particles.  It is 
available in various particle size and moisture grades.
Functional Categories : Adsorbent, Suspending Agent, Tablet and Capsule 
diluent and tablet disintegrant.
Tablet disintegrant :5-15%
Tablet diluent : 20-90%
Solubility : Slightly soluble in 5% sodium hydroxide practically insoluble in 
water.
Specific surface area 1.18m2g for avicel pH 101
pH : 5.0 to 7.0
Grade Bulk Density Tapped Density Nominal Mean
Particle Size
PH 101 0.320 g/cm3 0.386 g/cm3 50 Micro meter
PH 102 0.307 g/cm3 0.3709/Cm3 100 Micro Meter
Stability and storage conditions  :  It is hygroscopic and stable one and it 
should be stored in well closed container.
Incompatibilities  :  Incompatible with strong oxidizing agents.
Applications  :  It is widely used in pharmaceuticals and food products.  It is 
used as binder or diluent in oral tablet or capsule formulation where it is used 
in both wet granulation and direct compression.  It is also used as lubricant or 
disintigrant.
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3) MAGNESIUM STEARATE
It is also called as metallic stearate.  Chemically it is octadecanoic acid.
Empirical formula: C36H70MgO4
Molecular weight: 591.3
Description: Fine, white, precipitated or milled, impulpable powder of low bulk
density.  Odour  and  taste  are  slight  but  characteristic.   The  powder  is
unctuous, and readily adheres to the skin.
Density: 1.03 – 1.08 g/cm3
Stability and Storage Conditions:
Stable,  non-self-polymerizable,  store  in  a  cool,  dry  place  in  a  well-
closed container. 
Incompatibilities: 
Acidic substances, alkaline substances, iron salts, avoid mixing with 
strong oxidizing materials.  Use with caution with drugs which are 
incompatible with alkali.
Uses:
Tablet and capsule lubricant, glidant or antiadherent (0.25 – 2.0%).
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4) Carbomar
It is a high molecular weight polymer of acrylic acid cross linked with
allyl ether of sucrose 
It having different varieties of grade that are in such a  manner
Carbomer 934 
Carbomer 934 P
Carbomer 940
Carbomer 941
Carbomer  1342
Carbomer Co polymer
These trade are official U.S.P
Carbomer 934 P
It is a high molecular weight polymer of acrylic acid cross linked with
allyl ethers of sucrose.
It is dried in vaccum at 800 C for one Hour
It contains not less than 56.0% not more than 68% of COOH groups
The Viscosity of a neutralized 0.5% aqueous dispersion of carbomer
934 P is between Viscosity of this is between 29,400 & 39,400 centipoises.
Applications
Carbomer is used in 
 Sustained release
 Matrix beads
 Site specific drug delivery to esophagus
 Additionally used in preparation of SR Tablets. by using dry or
wet binder & as rate controlling excipient
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5) COLLOIDAL SILICON DIOXIDE
Synonyms:  Aerosil, Cab-O-sil, Colloidal silica, Fumed silica.
Description 
It is submicroscopic fumed silica with a particle size of about 15 nm. It
is a light, loose, bluish-white colored, odorless, tasteless, nongritty amorphous
powder.
Functional categories 
Adsorbent,  anticaking  agent,  glidant,  suspending  agent,  tablet
disintegrant, viscosity-increasing agent.
Solubility 
It  is  insoluble in water, organic solvents & acids, except hydrofluoric
acid. It is soluble in hot solution of alkali hydroxide.
Typical Properties
pH: 3.5 – 5.5
Loss on drying: ≤ 2.5%
Density (bulk): 0.029-0.042 gm/cm3
Density (tapped): 0.050 gm/ cm3
Stability and storage conditions
 It is hygroscopic & absorbs large quantities of water without liquefying.
Should be stored in well-closed container in a cool, dry place.
Incompatibilities  Incompatible with diethylstilbestrol preparation.
Applications 
It is widely used in pharmaceuticals, cosmetics & food products. It is
used as a glidant.  It  is  also used to stabilize emulsions & as a thixotropic
thickening & suspending agent in gels  & semisolid preparations.  It  is  also
used as tablet disintegrant. In aerosol, except those for inhalation, it is used to
promote  particulate  suspension,  eliminate  hard  settling  &  minimize  the
clogging of spray nozzles.
.
                                  5.5 PREFORMULATION STUDY93-94
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Preformulation  stability  studies  are  usually  the  first  quantitative
assessment of chemical stability of a drug as well as stability in presence of
other excipients.  The primary objectives of this investigation are identification
of  stable storage conditions for drug in the solid state and identification of
compatible excipients for a formulation.
Identification of Drug
The identification of drug was done by FT-IR Spectroscopy.
Method:  Triturate 1-2 mg of the substance to be examined with 300-400 mg,
unless otherwise specified, of finely powdered and dried potassium bromide
or potassium chloride .  These quantities are usually sufficient to give a disc of
10-15  mm  diameter  and  a  spectrum  of  suitable  intensity.   Infrared
spectrophotometers are used for recording spectra in the region of 4000 –
650.
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Drug – Excipient Compatibility Study :
Compatibility  studies  were  conducted  to  investigate  and  predict
physicochemical interaction between drug substance and excipents and
therefore to select suitability of chemically compatible excipients.
Table No.3
Physical observation of compatibility study :
Drug &
Excipients
(Ratio 1 : 1)
Observation Result
Initial 30oC±2/65%
±5 RH after
30 days
40oC±2/75%±5
RH after
30 days
Aceclofenac White to off
White powder
White to off
White powder
White to off
White powder
Compatible
Aceclofenac
+ HPMC K
15 M
White to off
White powder
White to off
White powder
White to off
White powder
Compatible
Aceclofenac
+ HPMC K 4
M
White to off
White powder
White to off
White powder
White to off
White powder
Compatible
Aceclofenac
+ Carbomer
934P
White to off
White powder
White to off
White powder
White to off
White powder
Compatible
Aceclofenac
+ PVP  K 30
White to off
White powder
White to off
White powder
White to off
White powder
Compatible
Aceclofenac
+ Mg.
Stearate
White to off
White powder
White to off
White powder
White to off
White powder
Compatible
Aceclofenac
+ Mcc
White to off
White powder
White to off
White powder
White to off
White powder
Compatible
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5.6 STANDARD CURVE OF ACECLOFENAC
Preparation of phosphate buffer pH 6.8
Accurately weighed quantity of 27.218 g of potassium dihydrogen
phosphate was dissolved in distilled water and diluted with distilled water
upto  1000  ml.  50ml  of  above  solution  was  taken  in  a  200  ml  of
volumetric flask, 22.4 ml of 0.2 M NaOH was added to the solution and
then diluted with distilled water upto volume. 
Preparation of standard curve in 6.8 pH buffer
100 mg equivalent weighed of Aceclofenac was dissolved in 100
ml of phosphate buffer pH 6.8.  The 10 ml of above solution was further
diluted upto 100 ml with phosphate buffer pH 6.8.  The resulting solution
was  serially  diluted  with  phosphate  buffer  pH  6.8.  to  get  drug
concentration 5,10,15,20,25 µg/ml. The absorbance of the solutions was
measured against phosphate buffer pH 6.8 as a blank at 274.0 nm using
double beam UV visible spectrophotometer..  The plot of absorbance v/s
concentration (µg/ml) was plotted and data was subjected to obtain linear
regression analysis.
Observation 
The standard calibration curve of drug in phosphate buffer pH 6.8
depicted as Figure. The data of absorbance was shown in Table . The data
had correlation coefficient of 0.9992.
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CHAPTER 6.
FORMULATION DEVELOPMENT
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6.1  Manufacturing  procedure  of  sustained  release  tablet  of
Aceclofenac
Wet Granulation Method
Weight  accurately  Drug  +  HPMC  K15M  +  PVP  K-30  and
Microcrystaline cellulose pass through 40 no sieves and mix properly for
3-5 minutes in a steel tub.
Prepare  binder  solution  by  dispersing  PVP  K30  in  isopropyl
alcohol.
Granulation of  above mixture  is  done by prepared  binder solution by
kneading up to granulation end point is obtained(Dough mass) .Pass the
dough mass through 12 mess and keep it in a tray dryer for drying and
finaly  keep  the  loss  on  drying(LOD)  up  to  2-3  %.Remove  the  dried
granules from oven and pass through 20 mess sieve to get optimum size
granules.Lubrication is done  by using Mg.stearate and  passed through
60 mesh of the granules for 3 to 4 min. in a steel tub and then in polybag.
Compression is done by using 16 station single rotary CADMACH
machine by using 9.6 mm round , biconcave ,both side plane punch .
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6.2 DESIGN AND DEVELOPMENT OF ACECLOFENAC SR
MATRIX TABLETS
Table No. 4
Formulation of Batch T-1 to T-5
Formulation
Ingredients
TRIAL  BATCHES
ASR - 01 ASR - 02 ASR - 03 ASR - 04 ASR – 05
Aceclofenac 200 200 200 200 200
MCC 67 63 62 74 72
PVP K – 30 10 9 10 8 10
I.P.A Q.S Q.S Q.S Q.S Q.S
HPMC K4M - 20 15 10 10
HPMC K 15 15 10 15 10 -
ACRYPOL
934 P 10 - - - 10
MAG
STEARATE 5 5 5 5 5
AEROSIL 3 3 3 3 3
TOTAL
WEIGHT 310 mg 310 mg 310 mg 310 mg 310 mg
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6.2.1 DESIGN AND DEVELOPMENT OF ACECLOFENAC SR
MATRIX TABLETS
Table No. 4.1
Formulation of Batch T-6 to T-10
Formulation
Ingredients
TRIAL  BATCHES
ASR - 06 ASR - 07 Final ASR - 09 ASR - 10
Aceclofenac 200 200 200 200 200
MCC 71 67 49 53 42
PVP K – 30 11 10 10 10 10
I.P.A Q.S Q.S Q.S Q.S Q.S
HPMC K4M - 10 - 20 25
HPMC K 15 5 10 23 - -
ACRYPOL
934 P 15 5 20 19 25
MAG
STEARATE 5 5 5 5 5
AEROSIL 3 3 3 3 3
TOTAL
WEIGHT 310 mg 310 mg 310 mg 310 mg 310 mg
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CHAPTER 7.
                     EVALUATION STUDIES
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7. EVALUATION STUDIES 93,95-98
7.1 EVALUATION OF GRANULES
7.1.1 Determination of bulk density and tapped density 
An accurately weighed quantity of the powder (W) was carefully
poured into the graduated cylinder and the volume (Vo) was measured
then  the  graduated  cylinder  was  closed  with  lid,  set  into  the  density
determination  apparatus  (Bulk  density  apparatus,  electrolab,  mumbai).
The density apparatus was set for 500 taps and after that, the volume (Vf)
was measured and continued operation till the two consecutive readings
were equal.  The bulk density and tapped density were calculated using
the following formulas:
Bulk density = W/Vo
Tapped density = W/Vf
Where 
Vo  =initial Volume 
Vf  = final Volume 
7.1.2 Compressibility index & Hausner Ratio
The Compressibility index and Hausner ratio are measures of the
property of a powder to be compressed. As such, they are measures of the
relative importance of inter particulate interactions.  In a free- flowing
powder, such interactions are generally less significant, and the bulk and
tapped densities will be closer in value.   For poorer flowing materials,
they  are  frequently  greater  inter  particle  interaction,  and  a  greater
difference between the bulk and tapped densities will be observed. These
differences  are  reflected in  the compressibility index and the Hausner
Ratio.  The compressibility index and Hausner ratio  may be calculated
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using measured values for bulk density (ρ bulk) and tapped density (ρ tapped )
as follows : 
ρ tapped - ρ bulk
compressibility index =    x 100
      ρ tapped
ρ tapped 
Hausner ratio =    
 ρ bulk
7.1.3 Loss on drying 
Determination of loss on drying of granules are important drying
time during granulation was optimized depending LOD value. LOD of
each batches were tested at 105○ c for 2.5 minutes by using “Sartorius”
electronic LOD apparatus. 
7.1.4 Angle of repose
The  flow  characteristics  are  measured  by  angle  of  repose.
Improper flow of powder is due to frictional forces between the particles.
These frictional forces are quantified by angle of repose. 
Angle of repose is defined as the maximum angle possible between
the surface of a pile of the powder and the horizontal plane. 
tan θ = h/r
θ = tan -1 h/r
where h = height of pile 
r = radius of the base of the pile 
θ = angle of repose
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Table No.5
Characterization of Trial Blends
B.No
Bulk
density*
Tapped
density*
Loss on
Drying in
%*
Compressibility
Index*
Hausner
Ratio*
Angle of
Repose( ο)*
T1 0.442 ±.
0.024
0.506 ±
0.014
1.7 ±
0.011
12.65 ± 0.015
1.14 ±
0.014
34ο±2
T2 0.486 ±
0.018
0.556 ±
0.026
1.2 ±
0.014
12.59 ± 0.022
1.14 ±
0.016
31ο±3
T3 0.529 ±
0.016
0.593 ±
0.021
1.5 ±
0.018
10.79 ± 0.021
1.12 ±
0.014
31ο±2
T4 0.512 ±
0.019
0.574 ±
0.025
1.4 ±
0.016
10.80 ± 0.019
1.12 ±
0.018
28ο±3
T5 0.544 ±
0.022
0.601 ±
0.022
1.4 ±
0.011
9.48 ± 0.014
1.10 ±
0.019
28ο± 2
T6 0.539 ±
0.017
0.586 ±
0.021
1.3 ±
0.013
8.02 ± 0.016
1.09 ±
0.021
26ο±3
T7 0.499 ±
0.018
0.564 ±
0.016
1.8 ±
0.017
11.52 ± 0.024
1.13 ±
0.022
32ο±2
T8 0.523 ±
0.018
0.602 ±
0.017
2.2 ±
0.012
13.12 ± 0.021
1.15 ±
0.017
35ο ±2
T9 0.524   ±
0.014
0.596 ±
0.024
1.5      ±
0.016
10.74 ± 0.019
1.14     ±
0.015
31ο ± 2
T10 0.527 ±
0.019
0.587   ±
0.024
1.2      ±
0.016
11.59 ± 0.017
1.13     ±
0.018
31ο ±  3
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7.2 EVALUATION OF TABLET
All  the  prepared  sustained  release  tables  were  evaluated  for
following official and unofficial parameters. 
7.2.1 Weight Variation
7.2.2 Dimensions
7.2.3 Hardness Test
7.2.4 Friability Test
7.2.5 Drug content
7.2.6 Dissolution study
7.2.1 Weight Variation 
           Method  
Twenty  tables  were  randomly  selected  form  each  batch  and
individually weighed.  The average weight an standard deviation of 20
tablets was calculated. The batch passes the test for weight variation test
if  not more then two of the individual tablet  weight  deviate from the
average weight by more than the percentage shown in Table 7 and none
deviate by more than twice the percentage shown. 
Observations:
The average weight and standard deviation of the tablets of each
batch were given in Table 6
                     Percentage deviation allowed under weight variation 
Percentage deviation allowed under weight variation test.
Average weight of tablet (X mg) Percentage deviation
X< 80 mg 10
80 < X < 250 mg 7.5
X > 250 mg 5
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7.2.2 Dimensions 
Twenty tablets were randomly selected form each batch and there
thickness and diameter was measured by using digital vernier caliper. 
Observations:
The average thickness and diameter with standard deviation of the
tablets of each batch were given in Table No.7
7.2.3 Hardness Test
Hardness was measured using Monsanto  hardness tester. For each
batch ten tablets were tested given in Table No.7 
Observations:
The measured hardness (N) of tablets of each batch was ranged
from 4-6 kg/cm2  
7.2.4 Friability Test
Twenty  tables  were  weighed  and  placed  in  the  Electorlab
friabilator  and  apparatus  was  rotated  at  25  rpm for  4  minutes.  After
revolutions the tablets were dedusted and weighed again. The percentage
friability was measured using the formula, 
% F = { 1- (Wt/W)} x 100
Where %F = friability in percentage
W = Initial weight of tablet
Wt = weight of tablet after revolution 
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Observations:
The results of measured % friability are given in Table 7 
Table No.7
Physical parameters of tables of each batch
B.No Weight
Variation
(mg)*
Thickness
(mm)*
Hardness
(kg/cm2)*
Friability
(%)
Drug
Content
(%)
T1 310±1.97 4.66±0.2 6 0.62±0.03 101.65
T2
310±1.68 4.63± 0.0 4 0.62±0.02 98.22
T3 310±3.05 4.37±0.3 4 0.42±0.05 103.99
T4 310±3.01 4.72±0.2 5 0.49±0.04 100.83
T5 310±1.84 4.69±0.3 6 0.65±0.03 96.98
T6 310±2.36 4.66±0.2 6 0.59±0.04 96.89
T7 310±3.14 4.60±0.3 4 0.67±0.02 96.42
T8 310±2.15 4.66±0.2 4 0.53±0.03 99.25
T9 310±3.14 4.60±0.3 6 0.65±0.03 99.73
T10 310±1.87 4.69±0.2 4 0.45±0.02 100.75
* Each value represents the mean ± standard deviation (n = 10) 
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7.2.5 Drug Content of Aceclofenac by HPLC 
Column : µ bonda pack C18  (1-30 cm; d = 4mm) Waters
Eluent : Add to 900 ml of water, 4 ml of ammonia 25% and 
5ml of conc. Phosphoric acid.  Shake and to bring on
pH  =  2.1  with  phosphoric  acid.   Add  100ml
acetonitril. Filtrate under vacuum 
Flow rate : 1.0 ml/min
Detection : 2.70 nm
Injection : 20 µl. Autosampler Spark Holland. 
Temperature : room temperature (15-25oC)
Solutions 
Standard : Accurately weigh 100 mg of Aceclofenac reference 
standard into a 100.0 ml volumetric flask, dissolve in
methanol and dilute to volume.
Sample to : Accurately weigh an amount of tablet powder, equal 
100mg  of  Aceclofenac into  a  100.0  ml  volumetric
flask,  and add methanol  to  volume.  Stir  during one
night to allow the Aceclofenac to dissolve.  Centrifuge
and inject the clear solution.
Calculation :
area Sa x th.wgh.S x wgh.St
----------- -----------------------  X 100%    =    assay %
area St X th. wgh. St x wgh. sa
Where :
area Sa = The area of the sample solution
area St = The area of the standard solution
                           Department of Pharmaceutics 75
                                                                                                                 Evaluation studies
th.wgh.St = The theoretical weight of the 
sample solution     
th.wgh.st = The theoretical weight of the 
standard solution
wgh.Sa = The real weight of the sample 
solution
wgh.St = The real weight of the standard 
solution
7.2.6 Dissolution Study
Medium : 6.8 pH phosphate buffer
Volume : 900ml
Apparatus : Paddle
Rotation : 75 rpm
Time : 24 hours
Detection : UV, 274nm
St. stock solution : Weigh an amount of Aceclofenac, 
reference  standard  equal  to  103.27  mg
Aceclofenac into a 100.0 ml volumetric
flask which was dissolve in medium 
Std. solution : Dilute 10.00 ml St, Stock solution to 
100ml with medium
Sample Solution : Take 10ml solution of sample from each 
vessel and filtered and take absorbance at
274  nm  on  double  beam  UV
spectrophotometer  and  replace  the
volume  with  dissolution  medium
maintaining the temperature. 
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Calculation :
Ex. S x th.wgh.St x 10 x 900 x purity 
…………………………………….. X 1000
Ex.St x wgh. St x 100 x 1 x  100
Where :
Ex.S = The extinction of the sample solution
Ex.St = The extinction of the standard solution
th.wgh.St = The theoretical weight of the reference 
standard  calculated  on  the  assay  of  the
reference standard
wgh.St = The real weight of the reference solution
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Table No.8
Dissolution Profile of batch No. T-1 to T-10  and marketed sample in
6.8 pH phosphate buffer
B.No
Time in Hours (cumulative % drug release)
6.8 PH buffer
0 2 4 8 12 16 24
T1
0 25.65 50.48 79.25 91.25 99.52 102.69
T2 0 22.68 40.17 72.58 89.24 97.77 100.25
T3 0 18.85 39.45 65.95 90.58 99.01 100.25
T4 0 20.65 40.25 72.56 92.68 99.67 102.58
T5 0 26.98 49.65 75.82 95.62 101.24 101.98
T6 0 24.98 42.78 70.98 85.24 92.57 101.69
T7 0 25.64 45.65 75.58 90.14 99.65 102.97
T8 0 15.56 25.63 69.85 82.46 92.05 99.56
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     T9 0 17.56 30.64 75.52 80.97 95.41 101.28
T10 0 14.69 22.57 65.24 75.68 88.52 97.24
Market
Sample 0 11.41 21.63 71.64 78.46 89.27 100.35
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Dissolution Profile of batch No. T-1 in 6.8 pH phosphate buffer 
Time in hours % Drug release
0 0
2 25.65
4 50.48
8 79.25
12 91.25
16 99.52
24 102.69
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Dissolution Profile of batch No. T-2 in 6.8 pH phosphate buffer
Time in hours % Drug release
0 0
2 22.68
4 40.17
8 72.58
12 89.24
16 97.77
24 100.25
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Dissolution Profile of batch No. T-3 in 6.8 pH phosphate buffer
Time in hours % Drug release
0 0
2 18.85
4 39.45
8 65.95
12 90.58
16 99.01
24 100.25
                           Department of Pharmaceutics 82
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Dissolution Profile of batch No. T-4 in 6.8 pH phosphate buffer
Time in hours % Drug release
0 0
2 20.65
4 40.25
8 72.56
12 92.68
16 99.67
24 102.58
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Dissolution Profile Of Batch T-4
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Dissolution Profile of batch No. T-5 in 6.8 pH phosphate buffer
Time in hours % Drug release
0 0
2 26.98
4 49.65
8 75.82
12 95.62
16 101.24
24 101.98
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Dissolution Profile of batch No. T-6 in 6.8 pH phosphate buffer
Time in hours % Drug release
0 0
2 24.98
4 42.78
8 70.98
12 85.24
16 92.57
24 101.69
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Dissolution Profile of batch No. T-7 in  6.8 pH phosphate buffer
Time in hours % Drug release
0 0
2 25.64
4 45.65
8 75.58
12 90.14
16 99.65
24 102.97
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Dissolution Profile Of Batch T-7
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Dissolution Profile of batch No. T-8 in 6.8 pH phosphate buffer
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Time in hours % Drug release
0 0
2 15.56
4 25.63
8 69.85
12 82.46
16 92.05
24 99.56
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Dissolution Profile Of Batch T-8
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Dissolution Profile of batch No. T-9 in 6.8 pH phosphate buffer
Time in hours % Drug release
0 0
2 17.56
4 30.64
8 75.52
12 80.97
16 95.41
24 101.28
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Dissolution Profile Of Batch T-9
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Dissolution Profile of batch No. T-10 in 6.8 pH phosphate buffer
Time in hours % Drug release
0 0
2 14.69
4 22.57
8 65.24
12 75.68
16 88.52
24 97.24
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Dissolution Profile Of Batch T-10
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Dissolution Profile of Market Sample in  6.8 pH phosphate buffer
Time in hours % Drug release
0 0
2 11.41
4 21.63
8 71.64
12 78.46
16 89.27
24 100.35
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Dissolution Profile Of Market Sample
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Comparative Dissolution profile of Batch T8 with marketed 
sample 
                  
Time  in
hours
Market  Sample Batch T8
0 0 0
2 11.41 15.56
4 21.63 25.63
8 71.64 69.85
12 78.46 82.46
16 89.27 92.02
24 100.35 99.56
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Comparative Dissolution profile of Batch T1-T10
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                             Determination of Similarity & Disimilarity  Factor
Table No.9
Disimilarity  Factor
Time
(hours) R T R-T SQR
MOD
(sqrt)
Cumulative
MOD
Cumulative
R F1
0 0 0 0 0 0 0 0 0
2 11.41 15.56 -4.15 17.22 4.15 4.15 11.41 36.37
4 21.63 25.63 -4 16 4 8.15 33.04 24.66
8 71.64 69.85 1.79 3.20 1.79 9.94 104.68 9.49
12 78.46 82.46 -4 16 4 13.94 183.14 7.61
16 89.27 92.02 -2.75 7.56 2.75 16.69 272.41 6.12
24 100.35 99.56 0.79 0.62 0.79 17.48 372.76 4.68
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Table No.10 
Similarity  Factor:
Time
in
(hours)
R T R-T (R-T)2
Cumulative
(R-T)2
Cum(R-
T)2*1/N
Cum(R-
T)2*1/N+1 SQRT 1/SQRT 100*1/SQRT
0 0 0 0 0 0 0 1 1 1 100
2 11.41 15.56 -4.15 17.22 17.22 2.87 3.87 1.96 0.50 50.83
4 21.63 25.63 -4 16 33.22 5.53 6.53 2.55 0.39 39.11
8 71.64 69.85 1.79 3.20 36.43 6.07 7.07 2.65 0.37 37.60
12 78.46 82.46 -4 16 52.42 8.73 9.73 3.12 0.32 32.04
16 89.27 92.02 -2.75 7.56 59.98 9.99 10.99 3.31 0.30 30.15
24 100.35 99.56 0.79 0.62 60.61 10.10 11.10 3.33 0.30 30.01
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CHAPTER 8.
STABILITY STUDY
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STABILITY STUDY OF TABLETS OF BATCH T894 
The batch T8 was selected as an optimum batch and the stability study
was carried out at accelerated condition.  of 40°C/75 % RH condition for a
period of two month. 
Method :
Ten  tablets  were  individually  wrapped  using  aluminum  foil  and
packed  in  ambered  color  screw  cap  bottle  and  put  at  above  specified
condition in incubator for 2 months. After two month tablets were evaluated
for content uniformity and in- vitro drug release. 
Observation :
The results of stability study after two month are given in Table 11 &
12 The plot of cumulative % drug release v/s Time (hr) depicted in graph.
Drug  content  : Comparative  content  uniformity  of  the  tablet  after  two
month stability. 
Table No.11
Drug content of batch T 8 kept for stability 
Time Drug Content (%)
Zero month 99.25
Two month 99.14
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                                                Table No.12
Dissolution profile of batch T-8 kept for stability
Dissolut-
ion 
Medium
Time (hrs) Cumulative % release
Initial Two month
0 0 0
2 15.56 14.12
4 25.63 23.69
6.8pH
buffer
8 69.85 69.12
12 82.46 81.78
16 92.02 91.23
24 99.56 99.31
 Dissolution profile of batch T-8 kept on stability at 40°C /75% RH
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CHAPTER 9.
                     RESULTS AND DISCUSSIONS 
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RESULTS AND DISCUSSION:
The procured sample of Aceclofenac was tested for its identification.
The manufacturer also was confirmed of quality and purity of sample.
The  drug  –  excipients  compatibility  was  done  at  accelerated
temperature  40oC/75%  ±  5%  and  30o  C/65%  ±  5%  relative  humidity.
Opened and closed vial methods were used.  The result doesn’t show any
physical change to the mixture after 30 days.  This fact concluded that the
drug and Excipient are compatible with each other.
The sustained release tablets of Aceclofenac were prepared by wet
granulation method, They were evaluated for weight variation, drug content,
friability, hardness, and thickness for all batches (T-1 – T-10).
No significant difference was observed in  the weight  of  individual
tablets from the average weight.  Tablet weights of all batches were found
with  in  recommended  pharmacopoeia  limits.   The  data  of  uniformity  of
content  indicated  that  tablets  of  all  batches  had  drug  content  within
pharmacopoeia  limits.   The  hardness  of  tablets  of  all  batches  are  in
acceptable limits, as shows in the literature.  All the formulation showed %
friability less then 1% that indicates ability of tablets to withstands shocks,
which  may  encounter.   No  significant  difference  was  observed  in  the
thickness of individual tablet from the average weight.
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Standard calibration curve of Aceclofenac was prepared in   phosphate
buffer   medium  6.8pH.Correlation  coefficient  values  indicate  the  linear
correlation between concentration and absorbance and following lamberts
beers law. 
The release of Aceclofenac from sustained release tablet of various
formulations varied according to the ratio and degree of the polymer.   In
case of tablet of T1containing drug & HPMCK15M (quantity in mg). 200:
15 :  the release profile,  was showing  the  release 102.69%.  In case of
tablets of T2 containing drug and HPMC K15M & HPMC K4M (in mg).
200:10:20 it was showing 100.25% release in 24 hours.  In case of tablets of
T3 containing drug polymer’s ( HPMCK15M, HPMCK4M in mg) 200 : 15 :
15 :   prepare to be seen in the effect of combination of  polymers in release
of drug but it was showing same release given 100.25% upto 24 hour.  In
case of tablets T4 containing drug and HPMC K15M & HPMCK 4M (in
mg) 200: 10: 10 the release profile was showing drug release more than
100% .In case of tablets of T5 containing drug and HPMC K 4M & HPMC
K15M PVP K30 (in mg) 200: 10: 10:10 .   Prepared the tablets.   But it
cannot maintain the release with in 100%. In case of tablets of T6 containing
drug and HPMC K 15M (in Mg) 200 : 5 .  It was seen the increase in release
of drug and shown more than 100%  drug release in 24 hour profile.  In case
of  tablets  T7,  containing  drug.   HPMCK4M  &  HPMCK15m  (in  mg)
200:10:10 the release profile was showing drug release more than 100%.  In
case of Tablets T8 containing drug.  HPMCK15M (in mg) 200 : 23.  The
release profile was showing drug release with in 24 hours.  With very slower
release than all formulations containing % drug release 99.56.
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In case of tablets T9, containing drug.  HPMCK4M  (in mg) 200:20 the
release profile was showing drug release more than 100%. In case of tablets
T10, containing drug.  HPMCK4M  (in mg) 200:25 the release profile was
showing drug release less than 100%.
For similarity, F2 calculation was done in 6.8 pH phosphate buffer showing
the value of similarity factor (F2) i.e., 73.9
Results of stability studies of batch T-8 indicates that it was stable at
40oC/75% + 5% relative humidity as there was no significant difference was
observed for dissolution and average drug content data after two months.
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10.Conclusion:
The  study  was  undertaken  with  an  aim  to  formulate  develop  and
evaluation of Aceclofenac sustained release tablets using different polymers
as release retarding agent.  Preformulation study of Aceclofenac was done
initially and results directed for the further course of formulation.  Based on
preformulation  studies  different  batches  were  prepared  using  selected
excipeints.  Granules were evaluated for tests LOD, Bulk density, tapped
density,  compressibility  index,  Hausner  ratio  before  being  punched  as
tablets.  Tablets were tested for weight variation, thickness, hardness and
friability as per official procedure.    Dissolution of batch T-8 was carried
out in 6.8 pH media and compared with marketed preparation.  Based on
dissolution  tests  and  F-2  values  in  pH  6.8  phosphate  buffer  as  release
medium, it was concluded that T-8 satisfactory performs in the same manner
as that  of  marketed formulation. F-2 (similarity factor)  value of T-6 was
found to be 73.90.
From the above results and discussion it is concluded that formulation
of sustained release tablet of Aceclofenac containing HPMC K 15M &  200 :
23 (in mg) T8 can be taken as an ideal or optimized formulation of sustained
release  tablets  for  24  hour  release  as  it  fulfills  all  the  requirements  for
sustained release  tablet  and  our  study encourages  for  the  further  clinical
trials on this formulation.
                    Department of  Pharmaceutics  101
                Conclusion 
                    Department of  Pharmaceutics  102
LIST OF TABLES
T.NO LIST OF TABLES PAGE.NO
CHAPTER – 5 EXPERIMENTAL INVESTIGATION
1 MATERIAL USED IN STUDY 41
2 INSTRUMENT USED IN STUDY 42
3 DRUG EXCIPIENT COMPATIBILITY STUDY 60
CHAPTER – 6 FORMULATION DEVELOPMENT
4 FORMULATION OF BATCH T-1 to T – 5 66
4.1 FORMULATION OF BATCH T -6 to T- 10 67
CHAPTER – 7 EVALUATION STUDIES 
5
CHARACTERIZATION OF TRIAL BLENDS 
71
6 % DEVIATION ALLOWED UNDER WEIGHT 
VARIATION
72
7 PHYSICAL PARAMETERS OF TABLETS OF  EACH
BATCH
74
8 DISSOLUTION PROFILE OF BATCH NO. T -1 to T- 
10 & MARKET SAMPLE  IN 6.8 pH PHOSPHATE 
BUFFER 
78
9 DISSIMILARITY FACTOR 92
10 SIMILARITY FACTOR 93
CHAPTER – 8 STABILITY  STUDIES
11 DRUG CONTENT OF BATCH T- 8 KEPT FOR 
STABILITY
95
12 DISSOLUTION PROFILE OF BATCH T- 8 KEPT 
FOR STABILITY
96
LIST OF FIGURES
S.NO LIST OF FIGURES PAGE.NO
CHAPTER –1 INTRODUCTION
1. HYPOTHETICAL DRUG BLOOD LEVEL – TIME COVERAGE 
FOR A CONVENTIONAL SOLID DOSAGE FORM AND A  
MULTIPLE ACTION PRODUCT
3
2. HYPOTHETICAL DRUG BLOOD LEVEL – TIME COVERAGE 
FOR A CONVENTIONAL SOLID DOSAGE FORM AND A  
MULTIPLE ACTION PRODUCT AND A CONTROLLED 
RELEASED PRODUCT TERMINOLOGY
3
3. PLASMA DRUG CONCENTRATION OF A SUSTAINED 
RELEASE AND A REGULAR RELEASE PRODUCT
4
4. SIMULATED PLASMA DRUG LEVEL OF A SUSTAINED 
RELEASE PRODUCT WITH A FAST RELEASE COMPONENT 
(A) AND A MAINTANANCE COMPONENT (B)
6
5. SIMULATED PLASMA DRUG LEVEL OF A SUSTAINED 
RELEASE PRODUCT ADMINISTERED EVERY 12 Hrs. 
6
6. RELATIONSHIP BETWEEN DRUG CONCENTRATION AND 
TIME FOR PRODUCTS POSSESSING VARIOUS RELEASE 
PROFILES
8
7. A HYPOTHETICAL PLASMA CONCENTRATION TIME 
PROFILE FROM CONVENTIONAL MULTIPLE DOSING AND 
A SINGLE DOSES OF SUSTAINED AND CONTROLLED 
DELIVERY FORMULATIONS.
13
8. SCHEMATIC REPRESENTATION OF SUSTAINED RELEASE 
DOSAGE SYSTEM
14
9. A HYPOTHETICAL PLASMA CONCENTRATION TIME 
PROFILE FROM SUSTAINED DRUG DELIVERY 
FORMULATION
14
10. MATRIX DIFFUSION SYSTEM BEFORE DRUG RELEASE 
(TIME =0) AND AFTER PARTIAL DRUG RELEASE (TIME =t)
19
11. DISSOLUTION OF DRUG FROM A SOLID MATRIX  SYSTEM 22
12 MATRIX  SYSTEM 23
13. SCHEMATIC SHOWING THE BURST EFFECT IN A ZERO – 
ORDER DRUG DELIERY SYSTEM
24
LIST OF GRAPHS 
CHAPTER –5 EXPERIMENTAL INVESTIGATION
1. FT –IR OF  ACECLOFENAC GRAPH 56
2. FT – IR OF CARBOMER 934P 57
3. FT – IR OF HPMC-  E5.M 58
4. FT – IR OF FORMULATION 59
5. SCANNING OF ACECLOFENAC IN PHOSPHATE BUFFER pH 6.8 62
6. STANDARD CURVE OF ACECLOFENAC IN PHOSPHATE 
BUFFER pH 6.8
63
CHAPTER – 7 EVALUATION STUDIES
9. DISSOLUTION PROFILE OF BATCH T-1 79
10. DISSOLUTION PROFILE OF BATCH T-2 80
11. DISSOLUTION PROFILE OF BATCH T-3 81
12. DISSOLUTION PROFILE OF BATCH T-4 82
13. DISSOLUTION PROFILE OF BATCH T-5 83
14. DISSOLUTION PROFILE OF BATCH T-6 84
15. DISSOLUTION PROFILE OF BATCH T-7 85
16. DISSOLUTION PROFILE OF BATCH T-8 86
17. DISSOLUTION PROFILE OF BATCH T-9 87
18. DISSOLUTION PROFILE OF BATCH T-10 88
19. DISSOLUTION PROFILE OF MARKET SAMPLE 89
20. COMPARATIVE STUDY OF BATCH 8 WITH MARKETED 
SAMPLE
90
21. COMPARATIVE STUDY OF BATCH T-1 to T- 10 91
CHAPTER –8 STABILITY  STUDY  
22. DISSOLUTION PROFILE OF OF STABILITY BATCH T-8 96
LIST OF ABBREVIATIONS
 PVP - POLYVINYL PYRROLIDONE
 HPMC - HYDROXY PROPYL METHYL CELLULOSE
 AEROSIL - COLLOIDAL SILICONE DIOXIDE
 FT- IR - FOURIER TRANSFROMER INFRA RED
 NSAIDS - NON STEROIDAL ANTI INFLAMMATORY DRUGS
NaOH             -          SODIUM HYDROXIDE
UV - ULTRA VIOLET
LOD - LOSS ON DRYING
HPLC - HIGH PERFORMANCE LIQUID  CHROMATOGRAPHY
I.P.A - ISOPROPYL ALCOHOL                           -               
SQRT                          -          SQURE ROOT           
MOD                          -             MEAN OF DEVIATION   
SR                              -             SUSTAINED RELEASE                                               
                                          
                Bibliography 
BIBLIOGRAPHY 
                    Department of  Pharmaceutics  102
                Bibliography 
BIBLIOGRAPHY
1. Yie. W. Chien “Novel drug delivery system", 2nd edition, 1 Pp.
2. Ashok V. Bhosale, Rahul V. Takawale, sanjay D.  Sawamy “oral noval
drug  delivery  system  “The  Eastern  pharmacist”,  September  2000,
41- 43 Pp.
3. Ansel’s  “Pharmaceutical dosage forms and Drug Delivery System”, loyd
V. Allen,Jr, Nchols G. Popovich, Howard C. Ansel, 8th edition, 260-275
Pp.
4. D.  M.  brahmankar,  Sunil  B.  Jaiswal  “Biopharmaceutics  and
Pharmacokinetics a Treatise, 2002 reprint, Vallabh prakashan, 335-337
Pp.
5. Thomas Wai- Yip Lee, Joseph R. Robinson, ‘Controlled- Release Drug-
Delivery Systems,’ Chapter-47 in Remington: “The science and practice
of pharmacy”, 20th edition, vol-1, 903 Pp.
6. N.K.  Jain,  “Advances  in  Controlled  and Novel  Drug  Delivery”,  CBS
publications, 268-269 Pp.  
7. Fiona Palmer, Marine Levina, Ali Rajabi Siahboomi, Colorcon Limited,
Flagshiphouse,  victory  way,  Dartford,  U.K.,  1-3(Article  entitled  -“
investigation  of  a  direct  compressible  metformin  HCl  500  mg  ER
formulation based onHypromellose”).
8. Oral extended release product lioydn, sanson, head, school of pharmacy
and  medical  sciences,  university  of  South  Australia,  Adelaide,  Aust
Preeser 1999, 22:88-90 Pp.
9. Thomas  wai-Yip  lee,  Joseph  R.  Robinson,  controlled-release  drug
delivery system’s, chapter - 47 in Remington “The Science and Practice
of Pharmacy”, 20th edition, vol-1, 303, 907-910 Pp.
                    Department of  Pharmaceutics  103
                Bibliography 
10.N.K.  Jain,  “Advances  in  controlled  and  Novel  Drug  Delivery”,  CBS
publications, 268-269 Pp. 
11.Gul Majed khan: “past and present status of controlled release matrixes”;
Asia network for scientific in permeation ISSN 1608-8689, 2001, vol 1
(5): 350-350 Pp.
12.www. Theannals.com/egi/content/abstract/37/5/701.
13.Thesis  paper  on  “Formulation  and  Evaluation  of  Sustained  Release
Rifampicin matrix tablets” September 2002. Leon Lachman, Herbert A.
Lieberman, joseph L. Kanig”.
14. Hamed  M.  Abdou,  “Dissolution characteristics  of  controlled  Release
systems”,  chapter  -12  in  “Dissolution  Bioavailability  and
bioequivalence,” 215-218 Pp.  
15.Leon Lachman, Herbert A. Liberman, Joseph L. Kanig, “The Theory and
Practice of Industries Pharmacy”, 3rd edition.
15. a) Chapter 14, in sustained Release Dosage forms, 430 - 456 Pp. 
15. b.) Chapter 11 in tablets; 317-324 Pp.
16.James swarbrick and James C:Boylan “Encyclopedia of Pharmaceutical
technology”, (vol 14); 304-307 Pp.
17.“Trend  in  oral  sustained  release  formulation  –1”,  H.  popli  and
S.N.Sharma,  Dept  of  pharmaceutics,  Jamia  Hamdard  College  of
Pharmacy, NewDelhi-110062.  The Eastern Pharmacist August 1989, Pp:
99.
18.Thomas wai- Yip, Lee, Joseph R.Robinson, “Controlled – release drug
delivery  system”,  chapter  -3,  in  method  to  achieve  sustained  drug
delivery, Vol -6, 132-134 Pp. 
19.Welling P.G., Dobrinska M.R. “Dosing considerations and bioavailability
assessment of controlled drug delivery systems” chapter 6 in “Controlled
                    Department of  Pharmaceutics  104
                Bibliography 
Drug Delivery : Fundamental and applications” edited by Robinson J.R.,
Vincent  Lee,  2nd edition,  Marcel  Dekker  Inc.,  volume  29,  1978:
254-289 Pp.
20.Lordi  J.G  “sustained  release  dosage form”  chapter  14  in  Theory  and
Practice  of  Industrial  Pharmacy”  edited  by  Leon  Lachman  et  al.,  3rd
edition, Varghese publishing house, 1991: 430-431 Pp. 
21.Kumar S., Sharma S.M. 1991 “Controlled Release Dosage Forms”, The
Eastern Pharmacist, September: 17-21 Pp.
22.Vincent Hon-Leung Lee and Joseph R. Robinson ‘Methods to Achieve
Sustained  Drug  Delivery-The  Physical  Approach:  Oral  and  Parentral
Dosage Forms’, Chapter-3, in “Sustained and Controlled Release Drug
Delivery System”, vol-6, 124-127 Pp.
23. “Sustained Release dosage form in Pharmaceutics and pharmaceutical
jurisprudence”, Piyush Publications 3.111-3.112 Pp.
24.Gilbert  S.  Banker,  Ghristopher  T.  Rhodes,  ‘Sustained  and  Controlled
Release Drug Delivery System,’ Chapter-16, in “Modern Pharmaceutics”
second edition, revised and expanded, vol-40, 641, 643-651 Pp.
25.Jems, T. Cartensen,” Advanced Pharmaceutical Solids”, Vol. 110, Drug
and the pharmaceutical sciences, 469 Pp.
26.Vincent  Hon-Leung  Lee  and  Joseph  R.  Robinson  “Drug  Properties
Influencing the Design of Sustained or Controlled Release Drug Delivery
Systems”,  Chapter-2,  in  “Sustained  and  Controlled  Release  Drug
Delivery Systems”, vol-6, 78-79 Pp.  
27.Mendes R.W., Ray S.B., Pharmaceutical Technology 2(9) (1978).
28.Abdul  Shajahan,  Poddar  S.  S.,  “A  flexible  technology  for  modified
release  of  drug:  multilayered  tablets",  journal  of  controlled  release
97(2004), 393-405 Pp.
                    Department of  Pharmaceutics  105
                Bibliography 
29.Franz M. R., Systma J. A., Smith B. P., Lucisano L. J., In vitro evaluation
of a  mixed polymeric  sustained release  matrix  using response surface
methodology, Journal of control release, 1987, 5, 159-172 Pp.
30.Harland R.S., A. Gazzaniga, M.E. Sangalli, P.colombo and N.A. Peppas,
1988, “Drug/Polymer matrix swelling and dissolution”, Pharmaceutical
Research, 5, 488-494 Pp.
31.S.K.Baveja,  A.V.Hassan  and  Amarjet  Singh,  “zero  order  release  of
pseudoephdrine hydrochloride from hydrophilic matrix tablets”.  Indian
journal  of  pharmaceutical,  sciences  November  -  December  1989:
248 – 251 Pp.
32.Gilberts,  Banker  et  al.1990,  “Modern  pharmaceutics”,  2nd edition,
647– 649 Pp.
33.H. Y.  Karasulu,  G. Ertan,  T.  Kose,  Modelling of theophylline release
from  different  –geometrical  erodable  tablets,  Europian  Journal  of
Pharmaceutics, 2000, 49: 177-182 Pp.
34.A.  T.  Pharm,  P.I.  lee,  “probing  the  mechanism of  drug  release  from
HPMC matrices, Pharm research, 1994, 11: 1379-1384 Pp.
35.T.  D.  Reynolds,  Polymer  erosion and drug release  characterization of
HPMC Matrices, Journal Pharma sciences, 1998, 87 (7): 1115-1123 Pp.
36.K.  Tahara,  Y.  Yamamoto,  T.  Nishikata,  “  overall  mechanism behind
matrix sustained release tablets prepared with HPMC” 2910, Journal of
control release, 1995, 35 :” 59-66 Pp.
37.R. V. Nellore, G. S. Rekhi, A. S. hussain, L.G. Tillman, L. L. Augsburger
“  development  of  metoprolol  tartrate  extended  release  matrix  tablet,
formulation  for  regulatory  policy  consideration,  Journal  of  Control
release, 1998, 50: 247-256 Pp.
                    Department of  Pharmaceutics  106
                Bibliography 
38.N.  D.  Edington,  G.  S.  Rekhi,  A.  S.  hussain,  L.G.  Tillman,  L.  L.
Augsburger “ Development and internal validation of an in vitro-in vivo
correlation for a hydrophilic metoprolol tartrate ER tablet formulation,
Pharm review, 1998,15: 466-471 Pp.
39.Verma, M.V. S. , A. M. Kaushal, A. Garg, S. Garg “ Factors affecting
mechanism and kinetics of drug release from matrix based oral control
drug delivery system” A J. Drug delivery, 2004, 2 : 43-57 Pp.
40.L.  Yang,  “Determination  of  continuous  changes  in  the  gel  layer  of
polyethylene  oxide  and HPMC tablet  undergoing  hydration:  a  texture
analysis study, Pharm. Research, 1998, 15: 1902-1096 Pp.
41.Popli  H.,  Sharma  S.H.,  1990,  “Evaluation  of  sustained  release
formulations”, The eastern pharmacist, January, 75 – 79 Pp.
42.Kumar  V.,  Damien  B.,  Potdar  A.R.,  1992,  “Designing  of  stability
programme,” The Eastern Pharmacist, August, 23 – 29 Pp.
43.Hogan,  J.E.  (1989)  Hydroxypropyimethylceliuiose  sustained  release
technology, Drug Development Industrial Pharmacy, 15, 975- 999 Pp.
44.Bettini,  R.,  Massimo,  G.,  Catellani,  P.L.,  Peppas,  N. A.,  Colombo,  P.
(1995) Zero order release by partial coating of HPMC matrix tablets with
permeable  and  semipermeable  films,  Proceed.  lst  World  Meeting
Pharmaceutics, Biopharm., Pharmaceutical Technology, 288-289 Pp.
45.Shenouda, L. S., Adams, K. A., Zogiio, M. A.(1990) A controlled release
delivery system using two hydrophilic polymers, International Journal of
Pharmaceutics. 61, 127-134 Pp.
46.Lee,  P.I.,  1980.  “Diffusional release of a solution from a polymerize
matrix approximate analytical solution”.  Journal of Membrane Science,
7: 255-275 Pp..
                    Department of  Pharmaceutics  107
                Bibliography 
47.Bettini, R., N.A. Peppas and P. Colombo, 1988, “polymer relaxation in
swellable matrixes  contributes  to  drug release,  produce int.  symptoms
control. Release  bioact. Mater., 25, 26-37 Pp.
48.Lee,  P.I.,  and C.Kim,  1991, “probing the mechanisms of drug release
form hydrogels”, Journal of controlled release, 16.229-236 Pp.
49.Paulo costa et al., “Modeling and Comparison of dissolution profiles”,
European journal of pharmaceutical science 13(2001):123-133 Pp. 
50.www. Theannals.com/egi/content/abstract/37/5/701
51.Kaushal  A.  et  al.2001,  “Regulatory  requirements  for  oral  controlled
release  drug  delivery  systems,”  Pharmacy  times,  volume  33,  April,
14 – 17 Pp.  
52.Skelly J.p., Barr W.H., “Regulatory assessment”  chapter – in “controlled
drug delivery fundamentals and applications”  edited by Robinson J. R.,
Vincent Lee, 2ndedition, Marcel Dekker inc., volume 29, 1978, 293 - 334
Pp.
53.C.  B.  Jha,  R.K.Rai,  S.K.Jaiswal,  A.J.Kadam,  S.Kumar,  The  Pharmac
Review-April 2006, p.85.
54.Roy.M.V.C.,  Proceedings  of  National  Sympsium  on  NIDDM,  4th
October, 1986, Appollo Hospital, Madras, P.14.
55.Bayer.A.G.,  A New Principle  in  the  treatment  of  diabetes  mellitus  –
Glucosidase inhibition by Acarbose, 1987, Mennen, Netherlands, P.48.
56.Who Study Group: Diabetes mellitus, Technical reports science, 1985,
WHO, Geneva, 727 Pp.
57.Laurance, D.R., and Bennettt, P.N., Clinical Biochemistry, 6th Ed., 1987,
ELBS/ Churchill Livingstone, U.K., 665 Pp.
58.Makol, Neelam, Elizabeth, A.M., Health Action, 2005, June: 4, 6 Pp.
                    Department of  Pharmaceutics  108
                Bibliography 
59.Remington, “The Science and Practice of pharmacy”, 20th Edn, vol.I,
pg.no.903-913.
60.Mohammed Reza siahi, (2005) “ Design and evaluation of 1 and 3 layer
matrices of Verapamil  for sustained release”  AAPS Pharm Sci Tech;
6(4) Article (7)
61 Lachman Leon, Liberman H.A and Kanig J.L., “The Theory and   
     Practice of Industrial Pharmacy” (3rd Edn), Varghese publishing House
     Bombay, pg.no. 171-195.
62.R.K.Khar, S.P.Vyas (2002) “ controlled drug delivery”ed. Pg. no.1-50  
63.Aulton M.E. “Hand Book of Pharamaceutics” Edition 2001, pg.no291-
     295.
64. Pather S.I,  Russell  I,  Neau S,  (1998) “Sustained release  theophylline
tablets  by  direct  compression  formulation  and  invitro  testing”  Int.  J.  of
pharm. 164, pg.no. 1-10. 
65. Qiu Y.Chidambaram N, Porter W. Flood K (1998), “Formulation and
characterization  of  new  diffusional  matrices  for  Zero  –  order  sustained
release” Jou. Cont. release, 52, pg.no. 149-158.
66. Cox P.J, Khan K.A., Munday D.L., Areevath J. (1999) “Development
and evaluation of multiple unit oral sustained  release form for Ibuprofen,
preparation and release kinetics” Int. J. Pharm, 193, Pg.no.73-84
67.T.Sing Hua, preparation of sodium valproate sustained release tablets and
evaluation  of  its  bioavailability  by  journal  of  china  pharmaceutical
university 2007.
68. Silvina A. Bravo, Maria C. Lamas, Claudio J.Salomon, (2002) “In-Vitro
Studies  of  Diclofenac  Sodium  Controlled  –  release  from  Biopolymeric
Hydrophilic Matrices” J.Pharm Pharmaceut Sci 5(3), pgno.213-219
                    Department of  Pharmaceutics  109
                Bibliography 
69. Reddy, K.R., Mutalik S, Reddy S, (2003) “Once daily sustained release
matrix  tablets  of  Nicorandil,  formulation  and  invitro evaluation”  AAPS
Pharm Sci tech 4 (4), 61.
70. Owen J. Corrigen, (2004) “ swelling and erosion properties of HPMC
matrices” International journals of pharmaceutics edition 279 year  page
no.141- 152  
71. Fenq Xm  “preparation and evaluation of a noval delayed onset sustained
release system of propanolol  hydrochloride” Institute of medical science
journal Pharm pharmcol P.No. 817 – 822
72. Hosseinali Tabandeh “Preparation of sustained release matrix tablets of
Aspirin with Eudragit RS100 and  Eudragit S 100 and studying the release
profiles and their sensitivity to tablet hardness” School of pharmacy, Iran
73.  Srinivasa  Mutalik,  2006  “Glipizide  matrix  transdermal  systems  for
diabetes mellitus” article life science :2006 May 6
74.  Jaleh  varshesaz,  (2006)  “  use  of  Hydrophilic  Natural  Gums  in
Formulation  of  sustained  –  release  matrix  Tablet  of  Tramodol
Hydrochloride”, AAPS Pharm Sci Tech; 7(1) Article 24
75. Yeole PG, Galgatte UC, (2006) “ Design and evaluation of xanthan gum 
– based sustained release Matrix tablets of Diclofenac sodium,” Indian 
Journal of pharmaceutical Science , , 185-189.
76.  Achutha  Nayak  Usha,  (2007)”  Preparation  ,  in  vitro,  preclinical  and
clinical studies of Aceclofenac spherical agglomerates” European journals of
pharmaceutics and Biopharmaceutics volume 70, Pg.No.674 – 683.
77. Mandal U  (2007) “ Formulation and optimization of sustained release
matrix  tablets  of  metformin  hydrochloride 500mg using response surface
methodology pg.No. 1281- 90 
                    Department of  Pharmaceutics  110
                Bibliography 
78.Srinivasa  Mutalik,  2007  “  Enhancement  of  dissolution  rate  and
bioavailability of aceclofenac” International journal of pharma 2007 sep –12
79. S. Mutalik “preparation in vitro, preclinical and clinical ealuations of
once  daily  sustained  release  tablets  of  Aceclofenac”  Arch  Pharm  2007
Pg.No. 222 – 34
80.Venkadari Gupta “Spherical crystals of celecoxib to improve solubility
dissolution rate and micro merits properties, Acta pharm 2007 pg.no. 173
-184
81.Meyyanathan SN 2008 “Formulation and evaluation of Detrometholphan
Hydrochloride bromide sustained release tablets,  Drug delivery Pg.no.429
-35
82. Li CJ “ Preparation of verapamil hydrochloride core in cup tablets with
double pulsatile and multiphasic release system
83. Sandip B. Tiwari, T.Krishna Murthy, M.Raveendra Pai, Pavak R. Mehta,
and  Pasula  B.  Chowdary  1  (2003)  Controlled  Release  Formulation  of
Tramadol  Hydrochloride  Using  Hydro-philic  and  Hydrophobic  Matrix
System “ AAPS Pharm. Sci. Tech, 4 (3) Article 31
84.Mandal  U  (2007)  “Formulation  and  optimization  of  sustained  release
matrix bilayer tablets “ drug delivery Indian Pharma 2008 pg.no. 305- 13.
85. www.cipla Therapeutic Index
86. www. TSR linc.com
87. Indian Pharmacopoeia 2007 edition
88. Prof. S.Saraf “ Drug Profile of Aceclofenac A Potent  Non – Steroidal
Anti – Inflammatory Drug  in JAMA, 1998.Pg.No. 147 -51
89.  Wade  Ainley,  Weller  P.J.,  “Hand  Book  of  Pharmaceutical
Excipients”,4th 1994, Pg.No. 71-73, 78-80, 82-83
                    Department of  Pharmaceutics  111
                Bibliography 
90.  Wade  Ainley,  Weller  P.J.,  “  Hand  Book  of  Pharmaceutical
Excipients”, 4th 1994, Pg.no.186-188, 223-227, 229-231, 562-563
91..Lachman Leon, Liberman H.A and Kanig J.L., “The Theory and 
Practice of Industrial Pharmacy”(3rd Edn) Varghese publishing House 
Bombay, Pg.No. 430-456
92.Remington “The science and practice of Pharmacy” 20th edition volume-
I, Page No –1030 –1033.
93..Lachman  Leon,  Liberman  H.A.  and  Kanig  J.L.,  “The  Theory  and
Practice  of  Industrial  Pharmacy”  (3rd Edn),  Vargheses  publishing  House
Bombay, pg.no. 443-453.171
94..Liberman, H.A. “Pharmaceutical Dossage Form; Tablets, “ second Edn,
Vol.I, pg.no. 201 – 213
95..“United State Pharmacopoeia” 26NF 21
96.“ Indian Pharmacopoeia” Volume II, 1996
97.“British Pharmacopoeia” 2004
98.“Europian Pharmacopoeia” 2003
                    Department of  Pharmaceutics  112
